Processes for preparing LP(a) inhibitors
Small molecule inhibitors of Lp(a) are developed to address the inadequacy of current therapies in reducing Lp(a) levels, offering a therapeutic solution for cardiovascular diseases and lipid disorders by effectively lowering plasma concentrations.
Patent Information
- Application Number
- PCT/US2026/027134
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Current pharmacologic therapies do not effectively reduce lipoprotein(a) concentrations, which are genetically determined and increase the risk of atherosclerotic cardiovascular disease, atherosclerosis, and calcific valvular aortic stenosis, necessitating the development of compounds that can lower plasma Lp(a) levels.
Development of small molecule inhibitors of lipoprotein(a) (Lp(a)) represented by compounds of Formula I and their pharmaceutically acceptable salts, which are designed to target and reduce Lp(a) levels.
The compounds effectively lower Lp(a) levels, providing a therapeutic option for patients with cardiovascular diseases and lipid disorders such as dyslipidemia and hypercholesterolemia.
Smart Images

Figure IMGF000002_0001 
Figure IMGF000010_0001 
Figure IMGF000010_0002
Abstract
Description
[0001] Atorney Docket No.: 777812: CAT-036PC
[0002] PROCESSES FOR PREPARING LP(A) INHIBITORS
[0003] CROSS REFERENCE TO RELATED APPLICATION
[0004] This application claims priority to U.S. Provisional Application No. 63 / 802,283, filed May 8, 2025, the contents of which are incorporated by reference herein in its entirety.
[0005] FIELD OF THE INVENTION
[0006] Described herein are compounds and processes for preparing small molecule inhibitors of lipoprotein(a) (Lp(a)).
[0007] BACKGROUND OF THE INVENTION
[0008] Lipoprotein(a) is a lipid-carrying particle composed of a low-density lipoprotein (LDL)-like particle containing apolipoprotein B100 (apoB100) linked by a disulfide bond to apolipoprotein(a). Lipoprotein(a) forms when apolipoprotein(a) and apoB100 bond together. Lipoprotein(a) is similar to low-density lipoprotein (LDL) cholesterol, sometimes called ’’bad cholesterol,” but is stickier and increases the risk of blockages in arteries. Plasma concentrations of lipoprotein(a) are primarily genetically determined (approximately 70 to > 90%), and its expression is controlled by the apolipoprotein(a) gene (LPA). Common LDL lowering drugs, such as statins, do not have the same lowering effect on lipoprotein(a). Diet, exercise, and other lifestyle changes are of little benefit in lowering lipoprotein(a) plasma concentrations.
[0009] Epidemiologic studies over the past three decades have shown an association between higher circulating lipoprotein(a) concentrations and an increased risk of atherosclerotic cardiovascular disease, atherosclerosis, and calcific valvular aortic stenosis.
[0010] Although lipoprotein(a) may be, on the basis of genetic data, a causal risk factor for atherosclerotic cardiovascular disease, no currently available pharmacologic therapies substantially reduce lipoprotein(a) concentrations or are indicated to treat patients with elevated lipoprotein(a) plasma concentrations. Accordingly, additional treatment options are desired for patients suffering from cardiovascular diseases, metabolic diseases, and lipid disorders such as dyslipidemia, hyperlipidemia, and hypercholesterolemia.
[0011] There is a need for synthesis procedures to make compounds that reduce plasma Lp(a) levels.
[0012] SUMMARY OF THE INVENTION
[0013] Provided herein are compounds and processes for preparing small molecule inhibitors of lipoprotein(a) (Lp(a)). In some embodiments, provided are compounds useful for
[0014] 1
[0015] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0016] preparing small molecule inhibitors of lipoprotein(a) (Lp(a)). In some embodiments, provided are compounds of Formula I*:
[0017] RPG2
[0018] 0
[0019] RA-^Y^Z
[0020]
[0021] rB(i*);
[0022] or pharmaceutically acceptable salts thereof, wherein the variables are as disclosed herein.
[0023] DETAILED DESCRIPTION OF THE INVENTION
[0024] Provided herein are compounds and processes for preparing small molecule inhibitors of Lp(a) and pharmaceutically acceptable salts thereof.
[0025] I. Definitions
[0026] At various places in the present specification, certain features of the compounds are disclosed in groups or in ranges. It is specifically intended that such a disclosure include each and every individual sub-combination of the members of such groups and ranges. For example, the term “C1-10 alkyl” is specifically intended to individually disclose (without limitation) methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl, Ce alkyl, C7 alkyl, Cs alkyl, C9 alkyl and C10 alkyl.
[0027] The term “n-membered,” where n is an integer, typically describes the number of ring-forming atoms in a moiety where the number of ring-forming atoms is n. For example, piperidinyl is an example of a 6-membered heterocycloalkyl ring, pyrazolyl is an example of a 5-membered heteroaryl ring, pyridyl is an example of a 6-membered heteroaryl ring and 1,2,3,4-tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group.
[0028] At various places in the present specification, variables defining divalent linking groups may be described. Where the structure requires a linking group, the Markush variables listed for that group are understood to be linking groups. For example, if the structure requires a linking group and the Markush group definition for that variable lists “alkyl” or “aryl” then it is understood that the “alkyl” or “aryl” represents a linking alkylene group or arylene group, respectively.
[0029] The term “substituted” means that an atom or group of atoms formally replaces hydrogen as a “substituent” attached to another group. The hydrogen atom is formally removed and replaced by a substituent. A single divalent substituent, e.g., oxo, can replace two hydrogen atoms. The term "optionally substituted" means unsubstituted or substituted. The term “substituted,” unless otherwise indicated, refers to any level of substitution, e.g., mono-, di-, tri-, tetra- or penta-substitution, where such substitution is permitted. The
[0030] 2
[0031] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0032] substituents are independently selected, and substitution may be at any chemically accessible position. It is to be understood that substitution at a given atom is limited by valency. It is to be understood that substitution at a given atom results in a chemically stable molecule.
[0033] The term “Cn-m” indicates a range which includes the endpoints, wherein n and m are integers and indicate the number of carbons present in a chemical moiety. The term is intended to include each and every member in the indicated range. Thus, Cn-mincludes each member in the series Cn, Cn+i, ... Cm-i, and Cm. Examples include CM (which includes Ci , C2, C3, and C4), C1-6 (which includes Ci, C2, C3, C4, C5, and Ce) and the like.
[0034] The term “alkyl” employed alone or in combination with other terms, refers to a saturated hydrocarbon group that may be straight-chained or branched. The term “Cn-malkyl,” refers to an alkyl group having n to m carbon atoms. An alkyl group formally corresponds to an alkane with one C-H bond replaced by the point of attachment of the alkyl group to the remainder of the compound. In some embodiments, the alkyl group contains from 1 to 6 carbon atoms, from 1 to 4 carbon atoms, from 1 to 3 carbon atoms, or 1 to 2 carbon atoms. Examples of alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, terf-butyl, isobutyl, sec-butyl; higher homologs such as 2-methyl-1 -butyl, n-pentyl, 3-pentyl, n-hexyl, 1,2,2-trimethylpropyl and the like.
[0035] The term “alkylene,” employed alone or in combination with other terms, refers to a divalent alkyl linking group. An alkylene group formally corresponds to an alkane with two C-H bonds replaced by points of attachment of the alkylene group to the remainder of the compound. The term “Cn-malkylene” refers to an alkylene group having n to m carbon atoms. Examples of alkylene groups include, but are not limited to, methylene, ethan-1 ,2-diyl, ethan-1 ,1-diyl, propan-1, 3-diyl, propan-1, 2-diyl, propan-1, 1-diyl, butan-1 ,4-diyl, butan-1 ,3-diyl, butan-1 ,2-diyl, 2-methyl-propan-1, 3-diyl and the like.
[0036] The term “alkenyl,” employed alone or in combination with other terms, refers to a straight-chain or branched hydrocarbon group corresponding to an alkyl group having one or more carbon-carbon double bonds. The term “Cn-malkenyl” refers to an alkenyl group having n to m carbon atoms. An alkenyl group formally corresponds to an alkene with one C-H bond replaced by the point of attachment of the alkenyl group to the remainder of the compound. In some embodiments, the alkenyl moiety contains 2 to 6 or 2 to 4 carbon atoms. Example alkenyl groups include, but are not limited to, ethenyl, n-propenyl, isopropenyl, n-butenyl, sec-butenyl, and the like.
[0037] The term “alkynyl,” employed alone or in combination with other terms, refers to a straight-chain or branched hydrocarbon group corresponding to an alkyl group having one or more carbon-carbon triple bonds. The term “Cn-malkynyl” refers to an alkynyl group having n 3
[0038] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0039] to m carbon atoms. An alkynyl group formally corresponds to an alkyne with one C-H bond replaced by the point of attachment of the alkyl group to the remainder of the compound. In some embodiments, the alkynyl moiety contains 2 to 6 or 2 to 4 carbon atoms. Example alkynyl groups include, but are not limited to, ethynyl, propyn-1-yl, propyn-2-yl, and the like.
[0040] The term “alkoxy,” employed alone or in combination with other terms, refers to a group of formula -O-alkyl, wherein the alkyl group is as defined above. The term “Cn-malkoxy” refers to an alkoxy group, the alkyl group of which has n to m carbons. Example alkoxy groups include methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), t-butoxy and the like. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. The term “Cn-m dialkoxy” refers to a linking group of formula -0-(Cn-m alkyl)-O-, the alkyl group of which has n to m carbons. Example dialkoxy groups include -OCH2CH2O- and OCH2CH2CH2O-. In some embodiments, the two O atoms of a Cn-m dialkoxy group may be attached to the same B atom to form a 5- or 6- membered heterocycloalkyl group.
[0041] The term “amino,” employed alone or in combination with other terms, refers to a group of formula -NH2, wherein the hydrogen atoms may be substituted with a substituent described herein. For example, “alkylamino” can refer to -NH(alkyl) and - N (alkyl)2.
[0042] The terms “halo,” “halide,” or “halogen,” used alone or in combination with other terms, refers to fluoro, chloro, bromo and iodo. In some embodiments, “halo” refers to a halogen atom selected from F, Cl, Br or I. In some embodiments, halo groups are F.
[0043] The term “pseudohalo,” “pseudohalide,” or “pseudohalogen,” used alone or in combination with other terms, refers to groups that behave substantially similar to halides. Such compounds can be used in the same manner and treated in the same manner as halides. Example pseudohalo groups include, but are not limited to, methanesulfonate (OMs), trifluoromethanesulfonate (OTf) and 4-methylbenzenesulfonate (OTs).
[0044] The term “haloalkyl” refers to an alkyl group in which one or more of the hydrogen atoms has been replaced by a halogen atom. The term “Cn-mhaloalkyl” refers to a Cn-m alkyl group having n to m carbon atoms and from at least one up to {2(n to m)+1} halogen atoms, which may either be the same or different. In some embodiments, the halogen atoms are fluoro atoms. In some embodiments, the haloalkyl group has 1 to 6 or 1 to 4 carbon atoms. Example haloalkyl groups include CF3, C2F5, CHF2, CH2F, CCI3, CHCI2, C2CI5 and the like. In some embodiments, the haloalkyl group is a fluoroalkyl group.
[0045] The term “perfluoroalkyl” refers to a haloalkyl group in which all hydrogen atoms have been replaced by fluorine atoms. Example perfluoroalkyl groups include CF3, C2F5, and C3F7.
[0046] The term “haloalkoxy,” employed alone or in combination with other terms, refers to a group of formula -O-haloalkyl, wherein the haloalkyl group is as defined above. The term “Cn-m haloalkoxy” refers to a haloalkoxy group, the haloalkyl group of which has n to m
[0047] 4
[0048] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0049] carbons. Example haloalkoxy groups include trifluoromethoxy and the like. In some embodiments, the haloalkoxy group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
[0050] The term “oxo” or “oxy” refers to an oxygen atom as a divalent substituent, forming a carbonyl group when attached to carbon, or attached to a heteroatom forming a sulfoxide or sulfone group, or an / V-oxide group. In some embodiments, heterocyclic groups may be optionally substituted by 1 or 2 oxo (=0) substituents. In some embodiments, heterocyclyl groups may be optionally substituted by 1 or 2 oxo (=0) substituents. In some embodiments, heterocyclic groups may be optionally substituted by 1, 2, 3, 4, or 5 oxo (=0) substituents. In some embodiments, heterocyclyl groups may be optionally substituted by 1, 2, 3, 4, or 5 oxo (=0) substituents.
[0051] The term “oxidized” in reference to a ring-forming N atom refers to a ring-forming N-oxide.
[0052] The term “oxidized” in reference to a ring-forming S atom refers to a ring-forming sulfonyl or ring-forming sulfinyl.
[0053] The term “carbonyl,” employed alone or in combination with other terms, refers to a -C(=0)- group, which also may be written as C(0).
[0054] The term “sulfonyl” refers to a -SO2- group wherein a sulfur atom is doubly bound to two oxygen atoms.
[0055] The term “aromatic” refers to a carbocycle or heterocycle having one or more polyunsaturated rings having aromatic character ( / .e., having (4n + 2) delocalized TT (pi) electrons where n is an integer).
[0056] The term “aryl,” employed alone or in combination with other terms, refers to an aromatic hydrocarbon group, which may be monocyclic or polycyclic (e.g., having 2 fused rings). The term “Cn-maryl” refers to an aryl group having from n to m ring carbon atoms. Aryl groups include, e.g., phenyl, naphthyl, and the like. In some embodiments, aryl groups have from 6 to about 10 carbon atoms. In some embodiments, aryl groups have 6 carbon atoms. In some embodiments, aryl groups have 10 carbon atoms. In some embodiments, the aryl group is phenyl. In some embodiments, the aryl group is naphthyl.
[0057] The term “heteroaryl” or “heteroaromatic,” employed alone or in combination with other terms, refers to a monocyclic or polycyclic aromatic heterocycle having at least one heteroatom ring member selected from sulfur, oxygen and nitrogen. In some embodiments, the heteroaryl ring has 1, 2, 3 or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, any ring-forming N in a heteroaryl moiety can be an N-oxide. In some embodiments, the heteroaryl has 5-14 ring atoms including carbon atoms and 1, 2, 3 or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl has 5-10 ring atoms including carbon atoms and 1, 2, 3 or 4 heteroatom ring members independently selected 5
[0058] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0059] from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl has 5-6 ring atoms and 1 or 2 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl is a five-membered or six-membered heteroaryl ring. In other embodiments, the heteroaryl is an eight-membered, nine-membered or ten-membered fused bicyclic heteroaryl ring. Example heteroaryl groups include, but are not limited to, pyridinyl (pyridyl), pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, azolyl, oxazolyl, isoxazolyl, thiazolyl, imidazolyl, furanyl, thiophenyl, quinolinyl, isoquinolinyl, naphthyridinyl (including 1,2-, 1,3-, 1,4-, 1,5-, 1,6-, 1,7-, 1,8-, 2,3- and 2,6-naphthyridine), indolyl, isoindolyl, benzothiophenyl, benzofuranyl, benzisoxazolyl, imidazo[1,2-b]thiazolyl, purinyl, and the like. In some embodiments, the heteroaryl group is pyridone (e.g., 2-pyridone).
[0060] A five-membered heteroaryl ring is a heteroaryl group having five ring atoms wherein one or more (e.g., 1, 2 or 3) ring atoms are independently selected from N, O and S.
[0061] Exemplary five-membered ring heteroaryls include thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1 ,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1 ,2,4-triazolyl, 1 ,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1 ,3,4-thiadiazolyl and 1,3,4-oxadiazolyl.
[0062] A six-membered heteroaryl ring is a heteroaryl group having six ring atoms wherein one or more (e.g., 1, 2 or 3) ring atoms are independently selected from N, O and S.
[0063] Exemplary six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl, isoindolyl, and pyridazinyl.
[0064] The term “heteroalkyl” (including “Ci-C6heteroalkyl” and “CrC3heteroalkyl”) refers to an alkyl group in which one or more, but not all, carbon atoms of the alkyl are each independently replaced with one heteroatom. In some embodiments, each heteroatom may be independently selected from the group consisting of oxygen, nitrogen, sulfur, boron, and phosphorous. A heteroalkyl is attached to the parent molecule at a carbon atom of the heteroalkyl. In some aspects, a heteroalkyl is a C C6heteroalkyl. In some aspects, a heteroalkyl is a CrC3heteroalkyl. A C3heteroalkyl comprises, in any order, either one carbon and two heteroatoms, or two carbons and one heteroatom.
[0065] The term “cycloalkyl” or "cycloalkane" employed alone or in combination with other terms, refers to a non-aromatic hydrocarbon ring system (monocyclic, bicyclic or polycyclic), including cyclized alkyl and alkenyl groups. The term “Cn-mcycloalkyl” or “Cn-mcycloalkane” refers to a cycloalkyl or cycloalkane that has n to m ring member carbon atoms. Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) groups and spirocycles. In the following, references to cycloalkyl groups apply equally to cycloalkane groups. Cycloalkyl groups can have 3, 4, 5, 6 or 7 ring-forming carbons (C3-7). In some embodiments, the cycloalkyl group has 3 to 6 ring members, 3 to 5 ring members, or 3 to 4
[0066] 6
[0067] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0068] ring members. In some embodiments, the cycloalkyl group is monocyclic. In some embodiments, the cycloalkyl group is monocyclic or bicyclic. In some embodiments, the cycloalkyl group is a C3-6 monocyclic cycloalkyl group. Ring-forming carbon atoms of a cycloalkyl group can be optionally oxidized to form an oxo or sulfido group. Cycloalkyl groups also include cycloalkylidenes. In some embodiments, cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings fused ( / .e., having a bond in common with) to the cycloalkyl ring, e.g., benzo or thienyl derivatives of cyclopentane, cyclohexane and the like. A cycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, bicyclo[1.1.1]pentanyl, bicyclo[2.1.1]hexanyl, and the like. In some embodiments, the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, the cycloalkyl group is tetrahydronaphthalenyl (e.g., 1,2,3,4-tetrahydronaphthalenyl).
[0069] The term “heterocycloalkyl” or "heterocycloalkane" employed alone or in combination with other terms, refers to a non-aromatic ring or ring system, which may optionally contain one or more alkenylene groups as part of the ring structure, which has at least one heteroatom ring member independently selected from nitrogen, sulfur, oxygen and phosphorus, and which has 4-10 ring members, 4-7 ring members, or 4-6 ring members. The term "n-m-membered heterocycloalkyl" or "n-m-membered heterocycloalkane" where n and m are integers refer to a heterocycloalkyl or heterocycloalkane ring or ring system containing from n to m ring-forming atoms. An n-m-membered heterocycloalkyl or heterocycloalkane includes from 1 to m-1 carbon atoms and from 1 to m-1 heteroatoms. The term "n-membered heterocycloalkyl" or "n-membered heterocycloalkane" where n is an integer refers to a heterocycloalkyl ring or ring system containing from n to m ring-forming atoms. In the following, references to heterocycloalkyl groups, rings or ring systems apply equally to heterocycloalkane groups, rings or ring systems. Included within the term “heterocycloalkyl” are monocyclic 4-, 5-, 6- and 7-membered heterocycloalkyl groups.
[0070] Heterocycloalkyl groups can include mono- or bicyclic (e.g., having two fused or bridged rings) or spirocyclic ring systems. In some embodiments, the heterocycloalkyl group is a monocyclic group having 1, 2 or 3 heteroatoms independently selected from nitrogen, sulfur and oxygen. Ring-forming carbon atoms and heteroatoms of a heterocycloalkyl group can be optionally oxidized to form an oxo or sulfido group or other oxidized linkage (e.g., C(O), S(O), C(S) or S(O)2, / V-oxide etc.) or a nitrogen atom can be quaternized. The heterocycloalkyl group can be attached through a ring-forming carbon atom or a ring-forming heteroatom. In some embodiments, the heterocycloalkyl group contains 0 to 3 double bonds.
[0071] 7
[0072] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0073] In some embodiments, the heterocycloalkyl group contains 0 to 2 double bonds. Also included in the definition of heterocycloalkyl are moieties that have one or more aromatic rings fused ( / .e., having a bond in common with) to the heterocycloalkyl ring, e.g., benzo or thienyl derivatives of piperidine, morpholine, azepine, etc. A heterocycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring. Examples of heterocycloalkyl groups include 2,5-diazabicyclo[2.2.1]heptanyl; pyrrolidinyl; hexahydropyrrolo[3,4-b]pyrrol-1(2 / 7)-yl; 1,6-dihydropyridinyl; morpholinyl; azetidinyl; piperazinyl; and 4,7-diazaspiro[2.5]octan-7-yl.
[0074] The term “halocycloalkyl” means cyclic hydrocarbon groups having the specified number of carbon atoms where a hydrogen atom (or hydrogen atoms) bonded to carbon atom is (are) arbitrarily substituted with a halogen atom (halogen atoms) and can form 3-membered to 10-membered hydrocarbon ring system (monocyclic, bicyclic or polycyclic). The indication of “Cn-Cmhalocycloalkyl” means mono- or polycyclic hydrocarbon groups having the number carbon atom number of a to b. In addition, each ring may be arbitrarily substituted alkyl group in the scope of the indicated carbon atom number. The substitution for halogen atom may be in the ring structure moiety, the side chain moiety or both of them. Further, if it is substituted with two or more halogen atoms, these halogen atoms may be identical with or different from each other. Concrete examples thereof are, for example, 2,2-dichlorocyclopropyl, 2,2-dibromocyclopropyl, 2,2-difluoro-1-methylcyclopropyl, 2,2-dichloro-1 -methylcyclopropyl, 2,2-dibromo-1-methylcyclopropyl, 2,2-dichloro-3,3-dimethylcyclopropyl, 2,2,3,3-tetrafluorocyclobutyl, 2-trifluoromethylcyclohexyl, 3-trifluoromethylcyclohexyl, 4-trifluoromethylcyclohexyl and the like.
[0075] The term “heterocycloalkenyl” refers to a partially unsaturated heterocyclyl.
[0076] Heterocycloalkenyl groups may be monocyclic (i.e. , a single ring) or multicyclic (i.e. , two or more rings). In some embodiments, a heterocycloalkenyl group is a monocyclic heterocycloalkenyl. In some embodiments, a heterocycloalkenyl group is a multicyclic heterocycloalkenyl. In some embodiments, the multicyclic heterocycloalkenyl is a spiro heterocycloalkenyl, a fused heterocycloalkenyl, a bridged heterocycloalkenyl, ora caged heterocycloalkenyl. In some embodiments, a heterocycloalkenyl group can have 3-14 ring members, 3-12 ring members, or 3-10 ring members.
[0077] The term “multicyclic carbocyclyl” refers to a ring system containing two or more carbocyclyl rings where each carbocyclyl ring shares at least one ring atom with at least one other carbocyclyl ring. In some embodiments, the multicyclic carbocyclyl is a spiro multicyclic carbocyclyl, a fused multicyclic carbocyclyl, a bridged multicyclic carbocyclyl, or a caged carbocyclyl. In some embodiments, the multicyclic carbocyclyl may contain two carbocyclyl rings (“bicyclic carbocyclyl”), three carbocyclyl rings (“tricyclic carbocyclyl”), four carbocyclyl 8
[0078] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0079] rings (“tetracyclic carbocyclyl”), or five carbocyclyl rings (“pentacyclic carbocyclyl”). In some embodiments, the multicyclic carbocyclyl is a bicyclic carbocyclyl. The bicyclic carbocyclyl may be, for example, a spiro bicyclic carbocyclyl, a fused bicyclic carbocyclyl, or a bridged bicyclic carbocyclyl. In some embodiments, a bicyclic carbocyclyl has 5 to 12 carbon atoms (e.g., a bicyclic C5-C12cycloalkyl).
[0080] The term “multicyclic heterocyclyl” refers to a multicyclic carbocyclyl where one or more of the carbon ring atoms has each been independently replaced with one heteroatom. In some embodiments, the multicyclic heterocyclyl is a spiro multicyclic heterocyclyl, a fused multicyclic heterocyclyl, a bridged multicyclic heterocyclyl, or a caged heterocyclyl. In some embodiments, the multicyclic heterocyclyl may contain two rings (“bicyclic heterocyclyl”), three rings (“tricyclic heterocyclyl”), four rings (“tetracyclic heterocyclyl”), or five rings (“pentacyclic carbocyclyl”). The bicyclic heterocyclyl may be, for example, a spiro bicyclic heterocyclyl, a fused bicyclic heterocyclyl, or a bridged bicyclic heterocyclyl. In some embodiments, a bicyclic heterocyclyl has 5 to 12 ring atoms (i.e. , a 5- to 12-membered bicyclic heterocyclyl).
[0081] The term “spiro carbocyclyl” refers to a multicyclic carbocycle where two of the carbocyclyls are joined together and share a single ring carbon atom. Spiro multicyclic carbocyclyls may contain two rings (“spiro bicyclic carbocyclyl”), three rings (“spiro tricyclic carbocyclyl”), four rings (“spiro tetracyclic carbocyclyl”), or five rings (“spiro pentacyclic carbocyclyl”). For example, the term “spiro bicyclic cycloalkyl” refers to a spiro bicyclic carbocycle containing two cycloalkyls that are joined together and share a single ring carbon atom. In some embodiments, a spiro bicyclic cycloalkyl has 5 to 12 carbon atoms (i.e., a spiro bicyclic Cs-C^cycloalkyl). Non-limiting examples of spiro bicyclic carbocyclyls include: spiro[2.2]pentyl, spiro[3.2]hexyl, spiro[3.3]heptyl, spiro[4.3]octyl, spiro[4.2]heptyl, spiro[5.3]nonyl, spiro[5.4]decanyl, spiro[5.5]undecanyl, spiro[5.2]octyl, spiro[6.3]decanyl, spiro[6.4]undecanyl, and spiro[6.5]dodecanyl.
[0082] The term “spiro heterocyclyl” refers to a spiro multicyclic carbocyclyl where one or more of the carbon ring atoms has each been independently replaced with one heteroatom. Spiro multicyclic heterocyclyls may contain two rings (“spiro bicyclic heterocyclyl”), three rings (“spiro tricyclic heterocyclyl”), four rings (“spiro tetracyclic heterocyclyl”), or five rings (“spiro pentacyclic heterocyclyl”). For example, the term “spiro bicyclic heterocycloalkyl” refers to a spiro bicyclic cycloalkyl where one or more of the carbon ring atoms has each been independently replaced with one heteroatom. In some embodiments, a spiro bicyclic heterocycloalkyl has 5 to 12 ring members. Non-limiting examples of spiro bicyclic heterocycloalkyls include:
[0083] 9
[0084] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0085]
[0086] The term “fused carbocyclyl” refers to a multicyclic carbocycle where two of the carbocyclyls are joined together and share two adjacent ring carbon atoms. Fused multicyclic carbocyclyls may contain two rings (“fused bicyclic carbocyclyl”), three rings (“fused tricyclic carbocyclyl”), four rings (“fused tetracyclic carbocyclyl”), or five rings (“fused pentacyclic carbocyclyl”). For example, the term “fused bicyclic cycloalkyl” refers to a ring system containing two cycloalkyls that are joined together and share two adjacent ring carbon atoms. In some embodiments, a fused bicyclic cycloalkyl has 5 to 12 carbon atoms (i.e., a fused bicyclic Cs-C^cycloalkyl). In some embodiments, a fused bicyclic cycloalkyl has 6 to 10 carbon atoms (i.e., a fused bicyclic Ce-C cycloalkyl). Non-limiting examples of fused bicyclic cycloalkyls include: bicyclo[4.4.0]decane, bicyclo[4.3.0]nonane, bicyclo[4.2.0]octane, bicyclo[4.1.0]heptane, bicyclo[3.3.0]octane, and bicyclo[3.1.0]hexane.
[0087] The term “fused heterocyclyl” refers to a fused multicyclic carbocyclyl where one or more of the carbon ring atoms has each been independently replaced with one heteroatom. Fused multicyclic heterocyclyls may contain two rings (“fused bicyclic heterocyclyl”), three rings (“fused tricyclic heterocyclyl”), four rings (“fused tetracyclic heterocyclyl”), or five rings (“fused pentacyclic carbocyclyl”). For example, the term “fused bicyclic heterocycloalkyl” refers to a fused bicyclic cycloalkyl where one or more of the carbon ring atoms has each been replaced with one heteroatom. In some embodiments, a fused bicyclic heterocycloalkyl has 5 to 125-12 ring members. In some embodiments, a fused bicyclic heterocycloalkyl has 6 to 10 ring members. Non-limiting examples of fused bicyclic heterocyclyls include:
[0088]
[0089] The term “bridged carbocyclyl” or “bridged bicycloalkyl” refers to a multicyclic carbocyclyl where two of the carbocyclyls are joined together and share three or more ring carbon atoms. Bridged multicyclic carbocyclyls may contain two rings (“bridged bicyclic carbocyclyl”), three rings (“bridged tricyclic carbocyclyl”), four rings (“bridged tetracyclic carbocyclyl”), or five rings (“bridged pentacyclic carbocyclyl”). For example, the term “bridged bicyclic cycloalkyl” refers to a ring system containing two cycloalkyls that are joined together and share three or more carbon atoms. In some embodiments, a bridged bicyclic carbocyclyl has 5 to 12 carbon atoms (e.g., a bridged bicyclic Cs-C^cycloalkyl). In some
[0090] 10
[0091] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0092] embodiments, a bridged bicyclic carbocyclyl has 5 to 8 carbon atoms (e.g., a bridged bicyclic Cs-Cscycloalkyl). Non-limiting examples of bridged bicyclic carbocyclyls include:
[0093] Structure Name
[0094] bicyclo[1.1.1]pentanyl
[0095] bicyclo[2.1.1]hexanyl
[0096] bicyclo[3.1.1 ]heptanyl
[0097] bicyclo[2.2.1]heptanyl
[0098] bicyclo[2.2.2]octanyl
[0099] bicyclo[3.2.2]octanyl
[0100] bicyclo[3.3.1]nonanyl
[0101] bicyclo[4.2.2]dodecanyl
[0102] bicyclo[3.3.2]dodecanyl
[0103] bicyclo[3.2.2]nonanyl
[0104] bicyclo[3.3.3]undecanyl
[0105] bicyclo[3.1.1 ]heptanyl
[0106]
[0107] For naming purposes, the following carbon numbering scheme for
[0108]
[0109] bicyclo[1.1.1]pentanyl (BCP) is used throughout the present disclosure:
[0110] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0111] The term “bridged cycloalkenyl” refers to a ring system containing 2 or more ring where at least one ring is a partially unsaturated carbocyclyl ring that contains one or more double bonds between adjacent ring carbons. The two or more rings are joined together and share three or more ring carbon atoms. In some embodiments, a bridged cycloalkenyl has 5 to 12 carbon atoms (e.g., a C5-C12 bridged cycloalkenyl). In some embodiments, a bridged bicyclic carbocyclyl has 5 to 8 carbon atoms (e.g., a Cs-Cs bridged bicycloalkenyl). Nonlimiting examples of bridged bicyclic carbocyclyls (bridged bicycloalkenyl) include:
[0112] Structure Name
[0113] bicyclo[2.1.1 ]hex-2-enyl
[0114] bicyclo[3.1.1 ]hept-2-enyl
[0115] 0
[0116] bicyclo[2.2.1]hept-2-enyl
[0117] bicyclo[2.2.2]oct-2-enyl
[0118] 0
[0119]
[0120] In some embodiments, examples of a bicycloalkenyl group include, but are not limited to, bicyclo[2.2.2]oct-2-ene, bicyclo[2.2.1]hept-2-ene, bicyclo[3.2.2]non-6-ene, and bicyclo[3.2.2]nona-2,6-diene.
[0121] The term “bridged heterocyclyl” refers to a bridged multicyclic carbocyclyl where one or more of the carbon ring atoms has each been independently replaced with one heteroatom. Bridged multicyclic heterocyclyls may contain two rings (“bridged bicyclic heterocyclyl”), three rings (“bridged tricyclic heterocyclyl”), four rings (“bridged tetracyclic heterocyclyl”), or five rings (“bridged pentacyclic carbocyclyl”). For example, the term “bridged bicyclic heterocycloalkyl” refers to a bridged bicyclic cycloalkyl where one or more, but not all, of the ring carbon atoms has each been independently replaced with one heteroatom. In some embodiments, a bridged bicyclic heterocyclyl has 5 to 12 atoms (i.e. , a 5- to 12-membered bridged bicyclic heterocycloalkyl). In some embodiments, a bridged bicyclic heterocyclyl has 5 to 8 atoms (e.g., a 5- to 8-membered bridged bicyclic heterocycloalkyl). Non-limiting examples of bridged bicyclic heterocyclyls include:
[0122] Structure Name
[0123] HN0>2-azabicyclo[1.1.1]pentane
[0124] 1 -azabicyclo[1.1.1]pentane
[0125]
[0126] 12
[0127] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0128] 5-oxabicyclo[2.1.1]hexane
[0129] 5-azabicyclo[2.1.1]hexane (JNH
[0130] 1 -azabicyclo[3.1.1 ]heptane 0
[0131] 6-oxabicyclo[3.1.1 ]heptane 0
[0132] 6-oxabicyclo[3.1.1 ]heptane
[0133] 3-oxa-1-azabicyclo[2.2.1]heptane 0o
[0134] 2-oxabicyclo[2.2.2]octane
[0135] N. 1 ,4-diazabicyclo[2.2.2]octane ^l\0
[0136] 2,4,8-trioxabicyclo[3.2.1]octane
[0137] (1R,5S)-3-azabicyclo[3.2.1]octane
[0138] NH
[0139] (1R,5S)-1-azabicyclo[3.2.1]octane A 4^0
[0140] H (1s,5s)-3,7-dioxa-9- N
[0141] azabicyclo[3.3.1]nonane
[0142] C\0^0
[0143] O
[0144] (1s,5s)-1,5- diazabicyclo[3.3.1]nonane
[0145] 0
[0146] (1R,6S)-3,7- 0 dithiabicyclo[4.2.2]decanes\00?
[0147] (1R,6S)-7-oxabicyclo[4.2.2]decane ^J^y0
[0148]
[0149] 13
[0150] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0151] Multicyclic carbocyclyls, as defined above, may contain three or more rings. For example, the term “tricyclic cycloalkyl” refers to a ring system containing three cycloalkyls joined together where each cycloalkyl shares at least one carbon atom with at least one other cycloalkyl. In some embodiments, a multicyclic carbocyclyl has 8 to 12 carbon atoms (i.e., a multicyclic Cs-C^cycloalkyl). Multicyclic carbocyclyls that contain three or more rings include caged carbocyclyls, spiro carbocyclyls, fused carbocyclyls, bridged carbocyclyls, or a combination thereof. In some embodiments, a multicyclic carbocyclyl is a caged carbocyclyl. Non-limiting examples of multicyclic carbocyclyls containing three or more rings include:
[0152] Structure IUPAC Name Common Name tricyclo[3.2.2.02’4]nonane N / A
[0153] or
[0154] tricyclo[5.2.1.02’6]decane N / A
[0155] or
[0156] tricyclo[2.2.2.21’4]decane N / A
[0157] tri cy cl o[ 1.1.1.01’3]pentane [1.1.1]propellane or
[0158] 1,2, 3, 4, 4a, 4b, 5, 6, 7, 8, 8a, 9, 10,1 tetradecahydrop Oa-tetradecahydrophenanthrene henanthrene
[0159] 2,3,4,5,6,7,8,9,10,11,12,13,14, hexadecahydro- 15,16,17-hexadecahydro-1 H- 1 / 7- cyclopenta[a]phenanthrene cyclopenta[a]phenanthre ne
[0160]
[0161] Multicyclic heterocyclyls, as defined above, may contain three or more rings. For example, the term “tricyclic heterocycloalkyl” refers to a tricyclic cycloalkyl where one or more ring carbon atoms of any one of the cycloalkyl rings has each been independently replaced with one heteroatom. In some embodiments, multicyclic heterocyclyls that contain three or more rings include caged heterocyclyls, spiro heterocyclyls, fused heterocyclyls, bridged heterocyclyls, or a combination thereof. In some embodiments, a multicyclic heterocyclyl is a caged heterocyclyl. In some embodiments, a multicyclic heterocyclyl has 5 to 12 ring members.
[0162] 14
[0163] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0164] The term “caged carbocyclyl” refers to a multicyclic carbocyclyl that contains three or more carbocyclyl rings and has a three-dimensional structure where each carbocyclyl ring forms a face of the three-dimensional structure. Caged carbocyclyls may contain, for example, three carbocyclyl rings, four carbocyclyl rings, five carbocyclyl rings, six carbocyclyl rings, seven carbocyclyl rings, or eight carbocyclyl rings. For example, the term “caged cycloalkyl” refers to a multicyclic cycloalkyls that contains four or more cycloalkyl rings and has a three-dimensional structure with each cycloalkyl ring forms a face of the three-dimensional structure. By definition, caged cycloalkyl moieties exclude bicyclic cycloalkyl moieties such as bicyclo[1.1.1]pentanyl. Furthermore, while all caged cycloalkyl groups are multicyclic cycloalkyl groups, not all multicyclic cycloalkyl groups are caged cycloalkyl groups. Non-limiting examples of caged cycloalkyls include:
[0165] Structur IUPAC Name Common Name
[0166] pentacyclo[4.2.0.02’5.03’8.04’7]octan cubane or
[0167] (1s, 2s, 3s, 4s, 6s, 7s) -cubane
[0168] 2
[0169] 3XT\,5
[0170] 7or
[0171] tricyclo[3.3.1.13J]decane adamantane
[0172] pentacyclo[3.3.0.02’4.03’7.06’8]octan cunane
[0173]
[0174] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0175] tricyclo[3.3.0.03’7]octane stellane or bisnoradamantane
[0176] or or
[0177] tetracyclo[3.3.1.13’7.01’3]decane 1,3- dehydroadamantane
[0178]
[0179] For naming purposes, the following carbon numbering scheme of cubane is used
[0180] throughout the present disclosure:
[0181]
[0182] The term “cubane,” “cubyl moiety,” etc., as used herein, refers to any carbon-containing ring having the fundamental structure of pentacyclo[4.2.0.02’5.03’8.04’7]octane (cubane), or a derivative thereof; and is further characterized as belonging to the prismane family. Chemically, prismanes are a series of fused cyclobutane rings that wrap around to join its ends and form a band, with cycloalkane edges. The generic chemical formula is (C2H2)n; e.g., when n = 4, the formula is ((C2H2)4) and the structure is cubane. As discussed herein, the cubyl moiety can be substituted or unsubstituted. Non-limiting examples of cubyl substituents include, but are not limited to, C1-C10 alkyl, C1-C10 haloalkyl, Ce-C aryl, C3-C10 cycloalkyl, C3-C10 halocycloalkyl, 5-10 membered heteroaryl, or halo.
[0183] The term “heteroatom” refers to any possible atom, other than carbon and hydrogen, that may appear within a molecule. Non-limiting examples of heteroatoms include atoms of the elements: boron, nitrogen, oxygen, sulfur, phosphorus, silicon, selenium, etc.
[0184] The term “caged heterocyclyl” refers to a caged carbocyclyl where one or more of the carbon atoms has each been independently replaced with one heteroatom. For example, the term “caged heterocycloalkyl” refers to a derivative of a caged cycloalkyl group where one or more of the carbon atoms has each been independently replaced with one heteroatom. By definition, caged heterocycloalkyl moieties exclude bicyclic heterocycloalkyl moieties such as 1-azabicyclo[1.1.1]pentane. Furthermore, while all caged heterocycloalkyl groups are multicyclic heterocycloalkyl groups, not all multicyclic heterocycloalkyl groups are caged heterocycloalkyl groups. Non-limiting examples of caged heterocycloalkyls include:
[0185] Structure IIIPAC Name (Common Name)
[0186]
[0187] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0188] 1-azatetracyclo[2.2.0.02’6.03’5]hexane (1-azaprismane)
[0189] 1-azapentacyclo[4.2.0.02’5.03’8.04’7]octane (1-azacubane) g
[0190] N—17
[0191] 1,4-diazapentacyclo[4.2.0.02’5.03’8.04’7]octane
[0192] N $—17
[0193] (3s,5s,7s)-1-azatricyclo[3.3.1.13’7]decane (1- azaadamantane)
[0194] (1 r,3r,5r,7r)-2,6-dioxatricyclo[3.3.1.13J]decane (2,6- dioxaadamantane)
[0195] u
[0196] 1-azapentacyclo[3.3.0.02,4.03,7.06,8]octane
[0197] 1-azatricyclo[3.3.0.03,7]octane
[0198] ^^0 2-oxatricyclo[3.3.0.03,7]octane
[0199] 4- oxa- 1 - azatri cy cl o[3.3.0.03 , 7] octa ne
[0200] N-j-^
[0201] 2-thiatricyclo[3.3.0.03,7]octane
[0202] 6-oxa-1,3-diazatricyclo[3.3.0.03,7]octane
[0203] 'Tv'0
[0204] N-r-(
[0205] (2r,3aR,5s,6aS)-dihydro-1H,3H,4H-2,5:3a,6a- dimethanocyclopenta[c]pyrrole
[0206]
[0207] At certain places, the definitions or embodiments refer to specific rings (e.g., an azetidine ring, a pyridine ring, etc.). Unless otherwise indicated, these rings can be attached to any ring member provided that the valency of the atom is not exceeded. For example, an azetidine ring may be attached at any position of the ring, whereas an azetidin-3-yl ring is attached at the 3-position.
[0208] In some embodiments, “one or more” refers to 1, 2, 3, or 4. In some embodiments, “one or more” refers to 1, 2, or 3. In some embodiments, “one or more” refers to 1 or 2. In some embodiments, “one or more” refers to 1.
[0209] 17
[0210] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0211] The compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated. Compounds of the present invention that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically inactive starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C=N double bonds and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms.
[0212] Resolution of racemic mixtures of compounds can be carried out by any of numerous methods known in the art. One method includes fractional recrystallization using a chiral resolving acid which is an optically active, salt-forming organic acid. Suitable resolving agents for fractional recrystallization methods are, e.g., optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids such as D-camphorsulfonic acid. Other resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of a-methylbenzylamine (e.g., S and R forms, or diastereomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine, 1,2-diaminocyclohexane and the like.
[0213] Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine). Suitable elution solvent composition can be determined by one skilled in the art.
[0214] When the compounds described herein contain a chiral center, unless otherwise indicated, the compounds can be any of the possible stereoisomers. In some embodiments, the compounds provided herein have the (R)-configuration. In other embodiments, the compounds have the (S)-configuration. In compounds with more than one chiral centers, each of the chiral centers in the compound may be independently (R) or (S), unless otherwise indicated. In compounds with a single chiral center, the stereochemistry of the chiral center can be (R) or (S). In compounds with two chiral centers, the stereochemistry of the chiral centers can each be independently (R) or (S) so the configuration of the chiral centers can be (R) and (R), (R) and (S); (S) and (R), or (S) and (S). In compounds with three chiral centers, the stereochemistry each of the three chiral centers can each be independently (R) or (S) so the configuration of the chiral centers can be (R), (R) and (R); (R), (R) and (S); (R), (S) and (R); (R), (S) and (S); (S), (R) and (R); (S), (R) and (S); (S), (S) and (R); or (S), (S) and (S).
[0215] 18
[0216] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0217] Compounds of the invention also include tautomeric forms. Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton. Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge. Example prototropic tautomers include ketone-enol pairs, amide - imidic acid pairs, lactam-lactim pairs, enamine-imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, e.g., 1 / 7- and 3 / 7-imidazole, 1 / 7-, 2 / 7- and 4 / 7- 1,2,4-triazole, 1 / 7- and 2 / 7- isoindole and 1 / 7- and 2 / 7-pyrazole. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution. Compounds herein identified by name or structure as one particular tautomeric form are intended to include other tautomeric forms unless otherwise specified (e.g., in the case of purine rings, unless otherwise indicated, if a compound name or structure described the 9 / 7 tautomer, it would be understood that the 7 / 7 tautomer is also encompassed).
[0218] Compounds of the invention can also include all isotopes of atoms occurring in the intermediates or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium. One or more constituent atoms of the compounds of the invention can be replaced or substituted with isotopes of the atoms in natural or non-natural abundance. In some embodiments, the compound includes at least one deuterium atom. For example, one or more hydrogen atoms in a compound of the present disclosure can be replaced or substituted by deuterium. In some embodiments, the compound includes two or more deuterium atoms. In some embodiments, the compound includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 deuterium atoms. In the compounds provided herein, any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom.
[0219] Substitution with heavier isotopes such as deuterium, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances. (A. Kerekes et.al. J. Med. Chem. 2011, 54, 201-210; R. Xu et.al. J. Label Compd. Radiopharm.
[0220] 2015, 58, 308-312). Unless otherwise stated, when a position is designated specifically as “D” or “deuterium,” the position is understood to have deuterium at an abundance that is at least 3000 times greater than the natural abundance of deuterium, which is 0.015% ( / .e., at least 45% incorporation of deuterium). In embodiments, the compounds provided herein have an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97%
[0221] 19
[0222] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0223] deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
[0224] The term “counterion” refers to an ion that accompanies an ionic species in order to maintain electric neutrality. A counterion is commonly referred to as an anion or a cation, depending on whether it is negatively or positively charged. Thus, the counterion to an anion will be a cation, and vice versa. In some embodiments, the counterion is selected from the group consisting of: F Cl Br, I BF4; HSOT, CN HCO3; NO3; and NCh'.
[0225] The term “chiral auxiliary” refers to a chiral functional group that can be installed on and removed from a molecule with the purpose of controlling the stereochemical outcome of a transformation of said molecule resulting in an enantioenriched or enantiopure product.
[0226] In some embodiments, the term “chiral auxiliary” refers to an oxazolidinone derivative. In some embodiments, the term “oxazolidinone derivative” refers to a moiety comprising an oxazolidinone core. In some embodiments, the oxazolidinone core is a 1,3-oxazolidin-2-one ring (i.e. , a cyclic carbamate):
[0227]
[0228] In some embodiments, the oxazolidinone core is a 1,3-oxazolidin-2-one ring and includes substituted and unsubstituted forms thereof. In some embodiments, an oxazolidinone derivative comprises an oxazolidinone core that is optionally substituted at one or more ring positions and / or at the ring nitrogen, and is optionally further substituted by one or more additional groups fused to, spiro-fused to, or pendant from the oxazolidinone core. In some embodiments, the oxazolidinone derivative includes any of the oxazolidinone-containing moieties exemplified herein, including the oxazolidinone-containing structures shown in the accompanying schemes and examples.
[0229] The term “protecting group” refers to a temporary chemical group added to a molecule to prevent a specific functional group from participating in an undesired reaction during a chemical transformation or synthesis. Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in P. Kocienski, Protecting Groups, 3rd Ed. (Thieme, 2005); J. Robertson, Protecting Group Chemistry, (Oxford University Press, 2000); M. B. Smith et al., March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 8th Ed. (Wiley, 2020); S. Petursson, J. Chem. Educ., 1997, 74(11), 1297-303; and P. G. M. Wuts et al., Greene's Protective Groups in Organic Synthesis, 5th Ed., (Wiley, 2014). Exemplary pyrrolidine protecting groups include, but are not limited to, Boc (tert- Butyloxycarbonyl), Fmoc (9-Fluorenylmethoxycarbonyl), Cbz (Benzyloxycarbonyl), Acetyl (Ac), Trityl (Triphenylmethyl),
[0230] 20
[0231] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0232] Benzyl (Bn), Allyl (All), p-Toluenesulfonamide (Ts), allyloxycarbonyl (Alloc), pivaloyl (Piv), trimethylsilyl (TMS), tert-butyldimethylsilyl (TBDMS), triisopropylsilyl (TIPS), 4-methylbenzenesulfonyl (Ms), 4-bromobenzenesulfonyl (BrMs), Phthalimide, and Trifluoroacetamide. Exemplary amine protecting groups include, but are not limited to, Boc (tert-Butyloxycarbonyl), Fmoc (9-Fluorenylmethoxycarbonyl), Cbz (Benzyloxycarbonyl), Acetyl (Ac), Trityl (Triphenylmethyl), Benzyl (Bn), Allyl (All), p-Toluenesulfonamide (Ts), allyloxycarbonyl (Alloc), pivaloyl (Piv), trimethylsilyl (TMS), tert-butyldimethylsilyl (TBDMS), triisopropylsilyl (TIPS), 4-methylbenzenesulfonyl (Ms), 4-bromobenzenesulfonyl (BrMs), Phthalimide, and Trifluoroacetamide. Additional exemplary pyrrolidine protecting groups include, but are not limited to, Boc (tert-Butyloxycarbonyl), Fmoc (9-Fluorenylmethoxycarbonyl), Cbz (Benzyloxycarbonyl), Acetyl (Ac), Trityl (Triphenylmethyl), Benzyl (Bn), Allyl (All), p-Toluenesulfonamide (Ts), allyloxycarbonyl (Alloc), propargyloxycarbonyl (Proc), pivaloyl (Piv), trimethylsilyl (TMS), tert-butyldimethylsilyl (TBDMS), triisopropylsilyl (TIPS), 4-methylbenzenesulfonyl (Ms), 4-bromobenzenesulfonyl (BrMs), Phthalimide, and Trifluoroacetamide, Teoc (2-(Trimethylsilyl)ethoxycarbonyl), Troc (2,2,2-Trichloroethoxycarbonyl), Azoc (Azidomethoxycarbonyl), p-Nitrobenzyloxycarbonyl (pNZ), 2-Chloro-benzyloxycarbonyl (2-CI-Z), Nosyl (Ns, Nitrobenzenesulfonyl), o-Nitrobenzenesulfonyl (oNBS), 2,4-Dinitrobenzenesulfonyl (dNBS), Benzothiazole-2-sulfonyl (Bts), 2-(4-Nitrophenylsulfonyl)ethoxycarbonyl (Nsc), Dde (1-(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl), ivDde (1-(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)isovaleryl), Mtt (4-Methyltrityl), Mmt (4-Methoxytrityl), Pbf (2, 2, 4,6,7-Pentamethyldihydrobenzofuran-5-sulfonyl), Pmc (2,2,5,7,8-Pentamethylchroman-6-sulfonyl), Mtr (4-Methoxy-2,3,6-trimethylbenzenesulfonyl), o-Nitrobenzyl (oNZ), NVOC (6-Nitroveratryloxycarbonyl), NPPOC (2-(2-Nitrophenyl)propoxycarbonyl). Exemplary carboxylic acid protecting groups include, but are not limited to, alkyl esters (e.g., Methyl (Me), Ethyl (Et), Benzyl (Bn), and t-Butyl (f-Bu) esters); silyl esters (e.g., Trimethylsilyl (TMS), tert-butyldimethylsilyl (TBDMS), and triisopropylsilyl (TIPS) esters); S-t-Butyl ester, 2-Alkyl-1 ,3-oxazoline, p-Methoxybenzyl (PMB) ester, Allyl (All) ester, diphenylmethyl ester, 1 ,3-dithian-2-yl-methoxycarbonyl (dM-Dim) ester, or ortho esters. In some embodiments, the carboxylic acid protecting group is a thiocarboxylic acid protecting group. In some embodiments, carboxylic acid protecting groups are interchangeable as thiocarboxylic acid protecting groups. Exemplary thiocarboxylic acid protecting groups include, but are not limited to, alkyl esters (e.g., Methyl (Me), Ethyl (Et), Benzyl (Bn), and t-Butyl (f-Bu) esters); silyl esters (e.g., Trimethylsilyl (TMS), tert-butyldimethylsilyl (TBDMS), and triisopropylsilyl (TIPS) esters); S-t-Butyl ester, 2-Alkyl-1,3-oxazoline, p-Methoxybenzyl (PMB) ester, Allyl (All) ester, diphenylmethyl ester, 1,3-dithian-2-yl-methoxycarbonyl (dM-Dim) ester, or ortho esters
[0233] 21
[0234] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0235] The term “compound” is intended, unless otherwise specified, to include all stereoisomers, including without limitation, geometric isomers, configurational isomers, conformational isomers, rotational isomers, and atropisomers, of the structures depicted, including each of the embodiments thereof. The term is also intended to refer to compounds described herein regardless of how they are prepared, e.g., synthetically, through biological process (e.g., metabolism or enzyme conversion), or a combination thereof.
[0236] All compounds, and pharmaceutically acceptable salts thereof, can be found together with other substances such as water and solvents (e.g., hydrates and solvates) or can be isolated. When in the solid state, the compounds described herein and salts thereof may occur in various forms and may, e.g., take the form of solvates, including hydrates. The compounds may be in any solid-state form, such as a polymorph or solvate, so unless clearly indicated otherwise, reference in the specification to compounds and salts thereof should be understood as encompassing any solid-state form of the compound.
[0237] In some embodiments, the compounds provided herein, or salts thereof, are substantially isolated. “Substantially isolated” means that the compound is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation can include, e.g., a composition enriched in the compounds of the invention. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds of the invention, or salt thereof.
[0238] The phrase “pharmaceutically acceptable” refers to those compounds, materials, compositions and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[0239] The present disclosure also includes pharmaceutically acceptable salts of the compounds described herein, including any of the embodiments thereof. The term “pharmaceutically acceptable salts” refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present invention include the non-toxic salts of the parent compound formed, e.g., from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by 22
[0240] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0241] reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, EtOAc, alcohols (e.g., MeOH, EtOH, iso-propanol or butanol) or MeCN are preferred. Lists of suitable salts are found in A.R. Gennaro (Ed.), Remington's Pharmaceutical Sciences, 17thEd., (Mack Publishing Company, Easton, 1985), p. 1418, S. M. Berge etal., J. Pharm. Sci., 1977, 66(1), 1-19, S. Gaisford in A. Adejare (Ed.), Remington, The Science and Practice of Pharmacy, 23rdEd., (Elsevier, 2020), Chapter 17, pp. 307-14; S.M. Berge etal., J. Pharm. Sci., 1977, 66(1), 1-19, T. S. Wiedmann, etal., Asian J. Pharm. Sci., 2016; 11, 722-34. D. Gupta et al., Molecules, 2018, 23(7), 1719; P.H. Stahl etal., Handbook of Pharmaceutical Salts: Properties, Selection, and Use, (Wiley, 2002) and in P.H. Stahl et al., Handbook of Pharmaceutical Salts: Properties, Selection, and Use, 2ndEd. (Wiley, 2011). In some embodiments, the compounds described herein include the N-oxide forms.
[0242] Compounds of the invention, including salts thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of numerous possible synthetic routes, such as those in the Schemes below.
[0243] The reactions for preparing compounds of the invention can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially non-reactive with the starting materials (reactants), the intermediates or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected by the skilled artisan.
[0244] Preparation of compounds of the invention can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art. The chemistry of protecting groups is described, e.g., in P. Kocienski, Protecting Groups, 3rdEd. (Thieme, 2005); J. Robertson, Protecting Group Chemistry, (Oxford University Press, 2000); M. B. Smith et al., March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 8thEd. (Wiley, 2020); S. Petursson, J. Chem. Educ., 1997, 74(11), 1297-303; and P. G. M. Wuts et al., Greene's Protective Groups in Organic Synthesis, 5thEd., (Wiley, 2014).
[0245] Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g.,1H or13C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry or by chromatographic methods 23
[0246] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0247] such as high-performance liquid chromatography (HPLC) or thin layer chromatography (TLC).
[0248] II. Compounds
[0249] In an aspect, provided herein is a compound of Formula I**:
[0250] RpG2
[0251]
[0252] rB(I**);
[0253] or a pharmaceutically acceptable salt thereof;
[0254] wherein:
[0255] RPG2is a pyrrolidine protecting group;
[0256] RBis H, -C1-3 alkyl-Ce-w aryl, or-Ci-3 alkyl-Ce-w carbocyclyl; wherein -C1-3 alkyl-Ce-w aryl is optionally substituted with one or more of halo, pseudohalo, C1-3 alkyl, C1-3 haloalkyl, -C(O)H, -CC>2-(Ci-6 alkyl), 5- to 7-membered heterocycloalkyl, -CH2NR2, -CH2OR, -C(O)R, -CN, -N2X, or -NR2; and wherein -C1-3 alkyl-Ce-w carbocyclyl is optionally substituted with one or more of halo, pseudohalo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or -NR2;
[0257] each R is independently H or C1-3 alkyl;
[0258] X is a counterion; and
[0259] RAis RCAor RD;
[0260] wherein:
[0261] RCAis a chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative; and
[0262] RDis C1-6 alkyl, C1-6 heteroalkyl, or C1-3 heteroalkyl-Ce-w aryl; wherein each is optionally substituted with one or more of halo, C1-3 alkyl, or C1-3 alkoxy.
[0263] In an aspect, provided herein is a compound of Formula I*:
[0264] RPG2
[0265]
[0266] rB(I*);
[0267] or a pharmaceutically acceptable salt thereof;
[0268] wherein:
[0269] RPG2is a pyrrolidine protecting group;
[0270] RBis H, -C1-3 alkyl-Ce-w aryl, or-Ci-3 alkyl-Ce-w carbocyclyl; wherein -C1-3 alkyl-Ce-w aryl is optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -C(O)H, -CO2-(C1-6 alkyl), 5- to 7-membered heterocycloalkyl, -CH2NR2, -CH2OR, -C(O)R, -CN, -N2X, or- 24
[0271] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0272] NR2; and wherein -C1-3 alkyl-Ce-w carbocyclyl is optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;
[0273] each R is independently H or C1-3 alkyl;
[0274] X is a counterion; and
[0275] RAis RCAor RD;
[0276] wherein:
[0277] RCAis a chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative; and
[0278] RDis C1-3 heteroal kyl-Ce-w aryl, optionally substituted with one or more of halo, C1-3 alkyl, or C1-3 alkoxy.
[0279] In an embodiment, one or more is 1, 2, 3, or 4. In another embodiment, one or more is or 1, 2, or 3. In yet another embodiment, one or more is or 1 or 2. In still another embodiment, one or more is 1.
[0280] In an embodiment, the compound of Formula I** is a compound of Formula II**:
[0281] RPG2
[0282]
[0283] RB(II**),
[0284] or a pharmaceutically acceptable salt thereof;
[0285] wherein:
[0286] RPG2is a pyrrolidine protecting group;
[0287] RBis H, -C1-3 alkyl-Ce-w aryl, or -C1-3 alkyl-Ce-w carbocyclyl; wherein the -C1-3 alkyl-Ce-10 aryl is optionally substituted with one or more of halo, pseudohalo, C1-3 alkyl, C1-3 haloalkyl, -CH2NR2, -CH2OR, -C(O)R, -CN, -N2X, or-NR2; and the -C1.3 alkyl-C6-io carbocyclyl is optionally substituted with one or more of halo, pseudohalo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;
[0288] X is a counterion;
[0289] each R is independently H or C1-3 alkyl;
[0290] RPG2is a pyrrolidine protecting group; and
[0291] RCAis a chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative.
[0292] In an embodiment, the compound of Formula I* is a compound of Formula II*:
[0293] RPG2
[0294]
[0295] RB(II*),
[0296] or a pharmaceutically acceptable salt thereof;
[0297] 25
[0298] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0299] wherein:
[0300] RPG2is a pyrrolidine protecting group;
[0301] RBis H, -C1-3 alkyl-Ce-w aryl, or -C1-3 alkyl-Ce-w carbocyclyl; wherein the -C1-3 alkyl-Ce-10 aryl is optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NR2, -CH2OR, -C(O)R, -CN, -N2X, or-NR2; and the -C1-3 alkyl-Ce-w carbocyclyl is optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;
[0302] X is a counterion;
[0303] each R is independently H or C1-3 alkyl;
[0304] RPG2is a pyrrolidine protecting group; and
[0305] RCAis a chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative.
[0306] In another embodiment, the compound of Formula II* is a compound of Formula III*:
[0307] RPG2
[0308] 0
[0309]
[0310] wherein:
[0311] RPG2is a pyrrolidine protecting group; and
[0312] RCAis a chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative.
[0313] In an embodiment, the compound of Formula I** is a compound of Formula l-S*:
[0314] RPG2
[0315]
[0316] RB(|-S**);
[0317] or a pharmaceutically acceptable salt thereof;
[0318] wherein:
[0319] RBis H, -C1-3 alkyl-Ce-w aryl, or -C1-3 alkyl-Ce-w carbocyclyl; wherein the -C1-3 alkyl-Ce-w aryl is optionally substituted with one or more of halo, pseudohalo, C1-3 alkyl, C1-3 haloalkyl, -CH2NR2, -CH2OR, -C(O)R, -CN, -N2X, or-NR2; and the -C1.3 alkyl-Ce-w carbocyclyl is optionally substituted with one or more of halo, pseudohalo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;
[0320] each R is independently H or C1-3 alkyl;
[0321] RPG2is a pyrrolidine protecting group; and
[0322] RAis RCAor RD;
[0323] wherein:
[0324] 26
[0325] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0326] RCAis a chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative; and
[0327] RDis C1-3 heteroalkyl-Ce-w aryl, optionally substituted with one or more of halo, C1-3 alkyl, or C1-3 alkoxy.
[0328] In an embodiment, the compound of Formula I* is a compound of Formula I:
[0329] RPG2
[0330] Or-N'
[0331]
[0332] RB(I);
[0333] or a pharmaceutically acceptable salt thereof;
[0334] wherein:
[0335] RBis H, -C1-3 alkyl-Ce-w aryl, or -C1-3 alkyl-Ce-w carbocyclyl; wherein the -C1-3 alkyl-Ce-10 aryl is optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -C(O)H, -CC>2-(Ci-6 alkyl), 5- to 7-membered heterocycloalkyl, -CH2NR2, -CH2OR, -C(O)R, -CN, -N2X, or -NR2;, optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;
[0336] each R is independently H or C1-3 alkyl;
[0337] RPG2is a pyrrolidine protecting group; and
[0338] RAis RCAor RD;
[0339] wherein:
[0340] RCAis a chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative; and
[0341] RDis C1-3 heteroalkyl-Ce-w aryl, optionally substituted with one or more of halo, C1-3 alkyl, or C1-3 alkoxy.
[0342] In another embodiment, the compound of Formula I is a compound of Formula II:
[0343] RPG2
[0344]
[0345] or a pharmaceutically acceptable salt thereof;
[0346] wherein:
[0347] RBis H, -C1-3 alkyl-Ce-w aryl, or -C1-3 alkyl-Ce-w carbocyclyl; wherein the -C1-3 alkyl-Ce-w aryl is optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -CH2OH, -C(O)R, -CN, -N2X, or-NR2; and the -C1-3 alkyl-Ce-w carbocyclyl is optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;
[0348] RPG2is a pyrrolidine protecting group; and
[0349] 27
[0350] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0351] RCAis a chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative.
[0352] In another embodiment, the compound of Formula I is a compound of Formula II:
[0353]
[0354] (II),
[0355] or a pharmaceutically acceptable salt thereof;
[0356] wherein:
[0357] RBis H, -C1-3 alkyl-Ce-w aryl, or -C1-3 alkyl-Ce-w carbocyclyl; wherein the -C1-3 alkyl-Ce-10 aryl is optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -CH2OH, -C(O)R, -CN, -N2X, or-NR2; and the -C1-3 alkyl-Ce-w carbocyclyl is optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;
[0358] RPG2is a pyrrolidine protecting group; and
[0359] RDis C1-3 heteroal kyl-Ce-w aryl, optionally substituted with one or more of halo, C1-3 alkyl, or C1-3 alkoxy.
[0360] In yet another embodiment, the compound of Formula II is a compound of Formula III:
[0361] RPG2
[0362] O
[0363]
[0364] wherein:
[0365] RPG2is a pyrrolidine protecting group; and
[0366] RCAis a chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative.
[0367] In still another embodiment, the compound of Formula II is a compound of Formula IV:
[0368] RPG2
[0369]
[0370] R2(IV),
[0371] or a pharmaceutically acceptable salt thereof;
[0372] 28
[0373] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0374] wherein:
[0375] R2is halo, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-3 haloalkyl, -CH2NR2, -CH2O-PG, -CH2OR, -C(O)R, -CN, -N2X, or-NR2;
[0376] X is counterion;
[0377] each R is independently H or C1-3 alkyl;
[0378] PG is a protecting group;
[0379] RPG2is a pyrrolidine protecting group; and
[0380] RCAis a chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative.
[0381] In some embodiments, the compound of Formula II is a compound of Formula IV-2:
[0382] RPG2
[0383] N
[0384]
[0385] (IV-2),
[0386] or a pharmaceutically acceptable salt thereof;
[0387] wherein:
[0388] R2is halo, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-3 haloalkyl, -CH2NR2, -CH2O-PG, -CH2OR, -C(O)R, -CN, -N2X, or -NR2; -C1-3 alkyl-Ce- carbocyclyl, optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;
[0389] X is counterion;
[0390] each R is independently H or C1-3 alkyl;
[0391] PG is a protecting group;
[0392] RPG2is a pyrrolidine protecting group; and
[0393] RDis C1-3 heteroalkyl-Ce- aryl, optionally substituted with one or more of halo, C1-3 alkyl, or C1-3 alkoxy.
[0394] In some embodiments, provided is a compound of Formula Xlll-A:
[0395] RPG2
[0396] S
[0397]
[0398] >2
[0399] (Xlll-A),
[0400] or a pharmaceutically acceptable salt thereof,
[0401] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0402] wherein:
[0403] R2is halo, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-3 haloalkyl, -CH2NR2, -CH2O-PG, -CH2OR, -C(O)R, -CN, -N2X, -NR2, or-Ci-3 alkyl-Ce-w carbocyclyl; wherein -C1-3 alkyl-Ce-w carbocyclyl optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;
[0404] X is counterion;
[0405] each R is independently H or C1-3 alkyl;
[0406] PG is a protecting group;
[0407] RPG2is a pyrrolidine protecting group; and
[0408] R4is C1.3 alkyl, Ce-waryl, or -C1.3 alkyl-Ce-waryl.
[0409] In some embodiments, the compound of Formula II is a compound of Formula Xlll-A:
[0410] RPG2
[0411]
[0412] (Xlll-A),
[0413] or a pharmaceutically acceptable salt thereof,
[0414] wherein:
[0415] R2is halo, pseudohalo, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-3 haloalkyl, -CH2NR2, -CH2O-PG, -CH2OR, -C(O)R, -CN, -N2X, -NR2, or-Ci-3 alkyl-Ce-w carbocyclyl; wherein -C1-3 alkyl-Ce-w carbocyclyl optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;
[0416] X is counterion;
[0417] each R is independently H or C1-3 alkyl;
[0418] PG is a protecting group;
[0419] RPG2is a pyrrolidine protecting group; and
[0420] R4is Ci-6 alkyl, C6-i2aryl, or -C1.3 alkyl-C6-i2aryl.
[0421] In some embodiments, the compound of Formula II is a compound of Formula Xlll-A:
[0422] RPG2
[0423]
[0424] (Xlll-A),
[0425] or a pharmaceutically acceptable salt thereof,
[0426] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0427] wherein:
[0428] R2is halo, pseudohalo, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-3 haloalkyl, -CH2NR2, -CH2O-PG, -CH2OR, -C(O)R, -CN, -N2X, or-NR2;
[0429] X is counterion;
[0430] each R is independently H or C1-3 alkyl;
[0431] PG is a protecting group;
[0432] RPG2is a pyrrolidine protecting group; and
[0433] R4is C1-3 alkyl, C6-i2aryl, or -C1-3 alkyl-C6-i2aryl; wherein the -C1-3 alkyl-C6-i2aryl is optionally substituted by C2-6 alkoxy.
[0434] In some embodiments, R4is C1-3 alkyl, C6-i2aryl, or-Ci-3 alkyl-C6-i2aryl; wherein R4is optionally further substituted by halo or C1-6 alkoxy.
[0435] In an embodiment, the pyrrolidine protecting group is an amine protecting group. In another embodiment, the pyrrolidine protecting group is a tert-butyloxycarbonyl (Boc) protecting group.
[0436] In another embodiment, the amine protecting group is selected from 9-fluorenylmethyloxycarbonyl (Fmoc) and tert-butyloxycarbonyl (Boc).
[0437] In yet another embodiment, the carboxylic acid protecting group is a tert-butyl (tBu) protecting group.
[0438] In still another embodiment, RPG1is a tert-butyl (tBu) protecting group.
[0439] In an embodiment, RPG2is a tert-butyloxycarbonyl (Boc) protecting group.
[0440] In another embodiment, RPG3is a 9-fluorenylmethyloxycarbonyl (Fmoc) protecting group.
[0441] Il-a. PSE Chiral Auxiliary
[0442] In an embodiment, the compound of Formula III is a compound of Formula lll-A:
[0443] RPG2
[0444]
[0445] OH Me (Hl-A),
[0446] wherein:
[0447] RPG2is a pyrrolidine protecting group;
[0448] RA1and RA2are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RA1and RA2are each further optionally substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, or -OR; and
[0449] each R is independently H or C1-3 alkyl.
[0450] In another embodiment, the compound of Formula IV is a compound of Formula IV-A:
[0451] 31
[0452] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0453] RPG2
[0454]
[0455] R2(IV-A),
[0456] wherein:
[0457] R2is halo, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-3 haloalkyl, -CH2NR2, -CH2O-PG, -CH2OR, -C(O)R, -CN, -N2X, or-NR2;
[0458] X is counterion;
[0459] each R is independently H or C1-3 alkyl;
[0460] PG is a protecting group;
[0461] RPG2is a pyrrolidine protecting group;
[0462] RA1is C1-3 alkyl, C6-12 aryl, or 5-10 membered heteroaryl; and
[0463] RA2is C1-3 alkyl, C6-12 aryl, or 5-10 membered heteroaryl.
[0464] In yet another embodiment, the compound of Formula IV-A is a compound of Formula IV-A2:
[0465] RPG2
[0466]
[0467] wherein:
[0468] RPG2is a pyrrolidine protecting group;
[0469] RA1and RA2are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RA1and RA2are each further optionally substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[0470] each R is independently H or C1-3 alkyl.
[0471] 32
[0472] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0473] In yet another embodiment, the compound of Formula IV-A is a compound of Formula IV-A3:
[0474]
[0475] (IV-A3), wherein:
[0476] RPG2is a pyrrolidine protecting group;
[0477] RA1and RA2are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RA1and RA2are each further optionally substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR;
[0478] each R is independently H or C1-3 alkyl; and
[0479] Z is halo.
[0480] In an aspect, provided herein is a compound selected from the group consisting of:
[0481]
[0482] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0483]
[0484] or a pharmaceutically acceptable salt thereof.
[0485]
[0486] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0487]
[0488] or a pharmaceutically acceptable salt thereof.
[0489] In an aspect, provided herein is a compound selected from the group consisting of:
[0490]
[0491] 35
[0492] 82684654v1Atorney Docket No.: 777812: CAT-036PC / Boc
[0493]
[0494] or a pharmaceutically acceptable salt thereof.
[0495] 36
[0496] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0497] In an embodiment, a compound of the application is a compound selected from:
[0498]
[0499] or a pharmaceutically acceptable salt thereof.
[0500] In certain embodiments, RCAis:
[0501]
[0502] wherein:
[0503] RA1and RA2are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RA1and RA2are each further optionally substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, or -OR; and
[0504] each R is independently H or C1-3 alkyl.
[0505] In certain embodiments, RCAis:
[0506] RA1
[0507] pA2 ■ \
[0508] Y^N
[0509]
[0510] OH MeA
[0511] wherein:
[0512] RA1and RA2are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RA1and RA2are each further optionally substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, or -OR; and
[0513] each R is independently H or C1-3 alkyl.
[0514] Il-b. Imidazolidinone Chiral Auxiliary
[0515] In an embodiment, the compound of Formula III is a compound of Formula lll-B:
[0516] RPG2
[0517]
[0518] wherein:
[0519] RPG2is a pyrrolidine protecting group;
[0520] 37
[0521] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0522] RB1, R , and RB3are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RB1, RB2, and RB3are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[0523] each R is independently H or C1-3 alkyl.
[0524] In another embodiment, the compound of Formula IV is a compound of Formula IV-B:
[0525] RPG2
[0526]
[0527] R2(IV-B),
[0528] wherein:
[0529] R2is halo, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-3 haloalkyl, -CH2NR2, -CH2O-PG, -CH2OR, -C(O)R, -CN, -N2X, or -NR2; -C1-3 alkyl-Ce-w carbocyclyl, optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;
[0530] X is counterion;
[0531] each R is independently H or C1-3 alkyl;
[0532] PG is a protecting group;
[0533] RPG2is a pyrrolidine protecting group;
[0534] RB1, RB2, and RB3are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RB1, RB2, and RB3are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, -CN, -NR2, -OR; and
[0535] each R is independently H or C1-3 alkyl.
[0536] In another embodiment, the compound of Formula IV is a compound of Formula IV-B-a:
[0537] RPG2
[0538]
[0539] R2(IV-B-a),
[0540] wherein:
[0541] R2is halo, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-3 haloalkyl, -CH2NR2, -CH2O-PG, -CH2OR, -C(O)R, -CN, -N2X, or -NR2; -C1-3 alkyl-Ce-w carbocyclyl, optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;
[0542] X is counterion;
[0543] 38
[0544] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0545] each R is independently H or C1-3 alkyl;
[0546] PG is a protecting group;
[0547] RPG2is a pyrrolidine protecting group;
[0548] RB1is C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, -CN, -NR2, -OR; and
[0549] each R is independently H or C1-3 alkyl.
[0550] In yet another embodiment, the compound of Formula IV-B is a compound of Formula IV-B2:
[0551] RPG2
[0552]
[0553] (IV-B2),
[0554] wherein:
[0555] RPG2is a pyrrolidine protecting group;
[0556] RB1, RB2, and RB3are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RB1, RB2, and RB3are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[0557] each R is independently H or C1-3 alkyl.
[0558] In an aspect, provided herein is a compound selected from:
[0559]
[0560] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0561] or a pharmaceutically acceptable salt thereof.
[0562] In another aspect, provided herein is a compound selected from:
[0563]
[0564] or a pharmaceutically acceptable salt thereof.
[0565] In another aspect, provided herein is a compound selected from the group consisting of:
[0566]
[0567] , and;
[0568] or a pharmaceutically acceptable salt thereof.
[0569] In an aspect, provided herein is a compound having the structure of:
[0570] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0571]
[0572] or a pharmaceutically acceptable salt thereof.
[0573] In certain embodiments, RCAis:
[0574]
[0575] RB1
[0576] wherein:
[0577] RB1, RB2, and RB3are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RB1, RB2, and RB3are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[0578] each R is independently H or C1-3 alkyl.
[0579] In certain embodiments, RCAis:
[0580]
[0581] wherein:
[0582] RB1, RB2, and RB3are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RB1, RB2, and RB3are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[0583] each R is independently H or C1-3 alkyl.
[0584] In certain embodiments, RCAis:
[0585] O
[0586]
[0587] f}B1,
[0588] wherein:
[0589] RB1is C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, -CN, -NR2, -OR; and
[0590] each R is independently H or C1-3 alkyl.
[0591] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0592] ll-c. Oxazolidine Chiral Auxiliary
[0593] In an embodiment, the compound of Formula III is a compound of Formula lll-C:
[0594] RPG2
[0595]
[0596] wherein:
[0597] RPG2is a pyrrolidine protecting group;
[0598] RC1, RC2, and RC3are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RC1, RC2, and RC3are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[0599] each R is independently H or C1-3 alkyl.
[0600] In another embodiment, the compound of Formula IV is a compound of Formula IV-C:
[0601] RPG2
[0602]
[0603] R2(IV-C),
[0604] wherein:
[0605] R2is halo, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-3 haloalkyl, -CH2NR2, -CH2O-PG, -CH2OR, -C(O)R, -CN, -N2X, or -NR2; -C1-3 alkyl-Ce- carbocyclyl, optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;
[0606] X is counterion;
[0607] PG is a protecting group;
[0608] RPG2is a pyrrolidine protecting group;
[0609] RC1, RC2, and RC3are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RC1, RC2, and RC3are each further optionally substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[0610] each R is independently H or C1-3 alkyl.
[0611] In yet another embodiment, the compound of Formula IV-C is a compound of Formula IV-C2:
[0612] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0613]
[0614] (IV-C2),
[0615] wherein:
[0616] RPG2is a pyrrolidine protecting group;
[0617] RC1, RC2, and RC3are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RC1, RC2, and RC3are each further optionally substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[0618] each R is independently H or C1-3 alkyl.
[0619] In an aspect, provided herein is a compound selected from:
[0620]
[0621] or a pharmaceutically acceptable salt thereof.
[0622] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0623] In another aspect, provided herein is a compound selected from:
[0624]
[0625] or a pharmaceutically acceptable salt thereof.
[0626] In certain embodiments, RCAis:
[0627]
[0628] wherein:
[0629] RC1, RC2, and RC3are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RC1, RC2, and RC3are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[0630] each R is independently H or C1-3 alkyl.
[0631] In certain embodiments, RCAis:
[0632]
[0633] wherein:
[0634] 44
[0635] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0636] RC1, R , and RC3are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RC1, RC2, and RC3are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[0637] each R is independently H or C1-3 alkyl.
[0638] Il-d. Benzamide Chiral Auxiliary
[0639] In an embodiment, the compound of Formula III is a compound of Formula lll-D*:
[0640] RPG2
[0641] O O
[0642] Ph N
[0643]
[0644] or a pharmaceutically acceptable salt thereof;
[0645] wherein:
[0646] RPG2is a pyrrolidine protecting group.
[0647] In an embodiment, the compound of Formula III is a compound of Formula lll-D:
[0648] RPG2
[0649] N
[0650]
[0651] or a pharmaceutically acceptable salt thereof;
[0652] wherein:
[0653] RPG2is a pyrrolidine protecting group.
[0654] In another embodiment, the compound of Formula IV is a compound of Formula IV-
[0655] RPG2
[0656] N
[0657] Ph N
[0658]
[0659] (IV-D),
[0660] or a pharmaceutically acceptable salt thereof;
[0661] wherein:
[0662] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0663] R2is halo, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-3 haloalkyl, -CH2NR2, -CH2O-PG, -CH2OR, -C(O)R, -CN, -N2X, or -NR2; -C1-3 alkyl-Ce- carbocyclyl, optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;
[0664] X is counterion;
[0665] each R is independently H or C1-3 alkyl;
[0666] PG is a protecting group; and
[0667] RPG2is a pyrrolidine protecting group.
[0668] In yet another embodiment, the compound of Formula IV-D is a compound of Formula IV-D2:
[0669]
[0670] (IV-D2),
[0671] or a pharmaceutically acceptable salt thereof;
[0672] wherein:
[0673] RPG2is a pyrrolidine protecting group.
[0674] In an aspect, provided herein is a compound selected from:
[0675]
[0676] or a pharmaceutically acceptable salt thereof.
[0677] 46
[0678] 82684654v1Attorney Docket No.: 777812: CAT-036PC
[0679] In another aspect, provided herein is a compound selected from:
[0680]
[0681] thereof.
[0682] In certain embodiments, R
[0683]
[0684] CAis , or a pharmaceutically acceptable salt
[0685] thereof. In certain embodiments, R
[0686]
[0687] CAis , or a pharmaceutically acceptable salt thereof.
[0688] O
[0689]
[0690] , or a pharmaceutically acceptable salt thereof.
[0691] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0692] ll-e. Oxazolidinone Chiral Auxiliary
[0693] In an embodiment, the compound of Formula III is a compound of Formula lll-E:
[0694]
[0695] or a pharmaceutically acceptable salt thereof;
[0696] wherein:
[0697] RPG2is a pyrrolidine protecting group;
[0698] RE1is C1-3 alkyl, C6-12 aryl, or 5-10 membered heteroaryl; and
[0699] RE2is C1-3 alkyl, C6-12 aryl, or 5-10 membered heteroaryl.
[0700] In an aspect, provided herein is a compound of Formula (IV-E):
[0701]
[0702] (IV-E),
[0703] or a pharmaceutically acceptable salt thereof;
[0704] wherein:
[0705] R2is halo, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-3 haloalkyl, -CH2NR2, -CH2O-PG, -CH2OR, -C(O)R, -CN, -N2X, or -NR2; -C1-3 alkyl-Ce- carbocyclyl, optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;
[0706] X is counterion;
[0707] each R is independently H or C1-3 alkyl;
[0708] PG is a protecting group;
[0709] RPG2is a pyrrolidine protecting group;
[0710] RE1and RE2are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RE1and RE2are each further optionally substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR;
[0711] RE3and RE4are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RE1and RE2are each further optionally substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[0712] each R is independently H or C1-3 alkyl.
[0713] 48
[0714] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0715] In an embodiment, a compound of Formula (IV-E) is a compound of Formula (IV-E2):
[0716]
[0717] or a pharmaceutically acceptable salt thereof;
[0718] wherein:
[0719] RPG2is a pyrrolidine protecting group;
[0720] RE1and RE2are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RE1and RE2are each further optionally substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR;
[0721] RE3and RE4are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RE1and RE2are each further optionally substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[0722] each R is independently H or C1-3 alkyl.
[0723] In an aspect, provided herein is a compound selected from:
[0724] and
[0725]
[0726] or a pharmaceutically acceptable salt thereof.
[0727] 49
[0728] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0729] In an aspect, provided herein is a compound selected from:
[0730]
[0731] or a pharmaceutically acceptable salt thereof.
[0732] In an aspect, provided herein is a compound selected from:
[0733]
[0734] or a pharmaceutically acceptable salt thereof.
[0735] 50
[0736] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0737] In another aspect, provided herein is a compound selected from:
[0738]
[0739] or a pharmaceutically acceptable salt thereof.
[0740] In certain embodiments, RCAis:
[0741]
[0742] or a pharmaceutically acceptable salt thereof;
[0743] wherein:
[0744] RE1is C1-3 alkyl, C6-12 aryl, or 5-10 membered heteroaryl; and
[0745] RE2is C1-3 alkyl, Ce-12 aryl, or 5-10 membered heteroaryl.
[0746] ll-f. Dimeric Compounds
[0747] In an aspect, provided herein is a compound of Formula V:
[0748]
[0749] (V),
[0750] 82684654v1Attorney Docket No.: 777812: CAT-036PC
[0751] or a pharmaceutically acceptable salt thereof,
[0752] wherein:
[0753] R5is halo or pseudohalo;
[0754] RPG1is a carboxylic acid protecting group;
[0755] RPG2is a pyrrolidine protecting group; and
[0756] RPG3is an amine protecting group.
[0757] In an aspect, provided herein is a compound of Formula VI:
[0758] RPG2
[0759]
[0760] or a pharmaceutically acceptable salt thereof,
[0761] wherein:
[0762] RPG1is a carboxylic acid protecting group;
[0763] RPG2is a pyrrolidine protecting group;
[0764] RPG3is an amine protecting group;
[0765] RPG2is a pyrrolidine protecting group; and
[0766] RCAis a chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative.
[0767] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0768] In an aspect, provided herein is a compound of Formula Xr-1:
[0769] RpG2
[0770]
[0771] or a pharmaceutically acceptable salt thereof,
[0772] wherein:
[0773] each R4is C1-3 alkyl, C6-i2aryl, or-Ci-3 alkyl-C6-i2aryl
[0774] each RPG1, independently for each occurrence, is a carboxylic acid protecting group; and
[0775] each RPG2, independently for each occurrence, is an amine protecting group.
[0776] Il-g: Chiral Auxiliaries
[0777] In an embodiment, the chiral auxiliary (e.g., RCA) is any chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative.
[0778] In some embodiments, the chiral auxiliary is an oxazolidinone derivative.
[0779] In an embodiment, the chiral auxiliary is a pseudoephedrine derivative.
[0780] In another embodiment, the chiral auxiliary is a pseudoephedrine derivative having the structure of:
[0781] RA1
[0782]
[0783] OH Me
[0784] wherein:
[0785] RA1and RA2are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RA1and RA2are each further optionally substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[0786] each R is independently H or C1-3 alkyl.
[0787] In still another embodiment, the chiral auxiliary is an imidazolidinone derivative.
[0788] 53
[0789] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0790] In another embodiment, the chiral auxiliary is an imidazohdinone derivative having the structure of:
[0791]
[0792] wherein:
[0793] RB1, RB2, and RB3are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RB1, RB2, and RB3are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[0794] each R is independently H or C1-3 alkyl.
[0795] In yet another embodiment, the chiral auxiliary is an oxazolidine derivative.
[0796] In another embodiment, the chiral auxiliary is an oxazolidine derivative having the structure of:
[0797]
[0798] wherein:
[0799] RPG2is a pyrrolidine protecting group;
[0800] RC1, RC2, and RC3are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RC1, RC2, and RC3are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[0801] each R is independently H or C1-3 alkyl.
[0802] In an embodiment, the chiral auxiliary is a benzamide derivative.
[0803] In another embodiment, the chiral auxiliary is a benzamide derivative having the structure of:
[0804] RPG2
[0805]
[0806] In an embodiment, RPG2is Boc (tert-Butyloxycarbonyl), Fmoc (9-Fluorenylmethoxycarbonyl), Cbz (Benzyloxycarbonyl), Acetyl (Ac), Trityl (Triphenylmethyl), Benzyl (Bn), Allyl (All), p-Toluenesulfonamide (Ts), allyloxycarbonyl (Alloc), propargyloxycarbonyl (Proc), pivaloyl (Piv), trimethylsilyl (TMS), tert-butyldimethylsilyl
[0807] 54
[0808] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0809] (TBDMS), triisopropylsilyl (TIPS), 4-methylbenzenesulfonyl (Ms), 4-bromobenzenesulfonyl (BrMs), Phthalimide, and Trifluoroacetamide, Teoc (2-(Trimethylsilyl)ethoxycarbonyl), Troc (2,2,2-Trichloroethoxycarbonyl), Azoc (Azidomethoxycarbonyl), p-Nitrobenzyloxycarbonyl (pNZ), 2-Chloro-benzyloxycarbonyl (2-CI-Z), Nosyl (Ns, Nitrobenzenesulfonyl), o-Nitrobenzenesulfonyl (oNBS), 2,4-Dinitrobenzenesulfonyl (dNBS), Benzothiazole-2-sulfonyl (Bts), 2-(4-Nitrophenylsulfonyl)ethoxycarbonyl (Nsc), Dde (1-(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl), ivDde (1-(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)isovaleryl), Mtt (4-Methyltrityl), Mmt (4-Methoxytrityl), Pbf (2, 2, 4,6,7-Pentamethyldihydrobenzofuran-5-sulfonyl), Pmc (2,2,5,7,8-Pentamethylchroman-6-sulfonyl), Mtr (4-Methoxy-2,3,6-trimethylbenzenesulfonyl), o-Nitrobenzyl (oNZ), NVOC (6-Nitroveratryloxycarbonyl), or NPPOC (2-(2-Nitrophenyl)propoxycarbonyl).
[0810] In an aspect, provided herein is a chiral auxiliary wherein the chiral auxiliary is an oxazolidinone derivative.
[0811] In an aspect, provided herein is a chiral auxiliary wherein the chiral auxiliary is an oxazolidinone derivative having the structure of:
[0812]
[0813] wherein:
[0814] RE1and RE2are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RE1and RE2are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR;
[0815] RE3and RE4are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RE1and RE2are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[0816] each R is independently H or C1-3 alkyl.
[0817] III. Processes
[0818] In an aspect, provided herein is a process for preparing a compound of Formula XI*:
[0819] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0820] RPG2
[0821] O
[0822] x1YfR;
[0823]
[0824] or a pharmaceutically acceptable salt thereof,
[0825] wherein:
[0826] each X1is a heteroatom selected from O and S;
[0827] each RPG1, independently for each occurrence, is a carboxylic acid protecting group; and
[0828] each RPG2, independently for each occurrence, is an amine protecting group; wherein the process comprises hydrogenative coupling and reducing a compound of Formula XIII:
[0829]
[0830] (XIII*),
[0831] or a pharmaceutically acceptable salt thereof,
[0832] wherein:
[0833] X1is a heteroatom selected from O and S;
[0834] R2is halo, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-3 haloalkyl, -CH2NR2, -CH2O-PG, -CH2OR, -C(O)R, -CN, -N2X, or -NR2; -C1-3 alkyl-Ce- carbocyclyl, optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;
[0835] X is counterion;
[0836] each R is independently H or C1-3 alkyl;
[0837] PG is a protecting group;
[0838] to form the compound of Formula XI*.
[0839] 56
[0840] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0841] In an aspect, provided herein is a process for preparing a compound of Formula XI:
[0842]
[0843] (XI),
[0844] or a pharmaceutically acceptable salt thereof,
[0845] wherein:
[0846] each RPG1, independently for each occurrence, is a carboxylic acid protecting group; and
[0847] each RPG2, independently for each occurrence, is an amine protecting group; wherein the process comprises hydrogenative coupling and reducing a compound of Formula XIII:
[0848] RPG2
[0849]
[0850] or a pharmaceutically acceptable salt thereof,
[0851] to form the compound of Formula XI.
[0852] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0853] In another aspect, provided herein is a process for preparing a compound of Formula XI:
[0854] RPG2
[0855]
[0856] (XI),
[0857] or a pharmaceutically acceptable salt thereof,
[0858] wherein:
[0859] each RPG1, independently for each occurrence, is a carboxylic acid protecting group; and
[0860] each RPG2, independently for each occurrence, is an amine protecting group; wherein the process comprises reducing a compound of Formula II:
[0861]
[0862] (XII),
[0863] to form the compound of Formula XI.
[0864] 58
[0865] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0866] In another aspect, provided herein is a process for preparing a compound of Formula XII:
[0867]
[0868] or a pharmaceutically acceptable salt thereof,
[0869] wherein:
[0870] each RPG1, independently for each occurrence, is a carboxylic acid protecting group; and
[0871] each RPG2, independently for each occurrence, is an amine protecting group; wherein the process comprises hydrogenative self-coupling of a compound of Formula XIII:
[0872] RPG2
[0873]
[0874] to form a compound of Formula XII.
[0875] In an embodiment, the hydrogenative cross-coupling comprises reacting the compound of Formula (III) with a catalyst.
[0876] In yet another embodiment, the catalyst is Raney nickel.
[0877] In an aspect, provided herein is a process for preparing a compound of Formula XIII:
[0878] 59
[0879] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0880] RPG2
[0881]
[0882] or a pharmaceutically acceptable salt thereof,
[0883] wherein:
[0884] RPG1is a carboxylic acid protecting group; and
[0885] RPG2is an amine protecting group;
[0886] wherein the process comprises performing a substitution on a compound of Formula XIV:
[0887] RPG2
[0888]
[0889] wherein:
[0890] R2is Cl, I, or pseudohalo;
[0891] to form the compound of Formula XIII.
[0892] In an embodiment, the substitution comprises performing an SNAr reaction.
[0893] In an aspect, provided herein is a process for preparing a compound of Formula XIV:
[0894] RPG2
[0895]
[0896] R2(XIV),
[0897] or a pharmaceutically acceptable salt thereof,
[0898] wherein:
[0899] R2is Cl, I, or pseudohalo;
[0900] RPG1is a carboxylic acid protecting group; and
[0901] RPG2is an amine protecting group;
[0902] wherein the process comprises protecting a compound of Formula XV:
[0903] 60
[0904] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0905]
[0906] (XV),
[0907] to form the compound of Formula IV.
[0908] In an aspect, provided herein is a compound selected from the group consisting of:
[0909]
[0910] In an aspect, provided herein is a compound having the following structure:
[0911] Boc
[0912]
[0913] NHFmoc
[0914] In another aspect, provided herein is a compound selected from the group consisting of:
[0915]
[0916] 61
[0917] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0918]
[0919] In another aspect, provided herein is a process for preparing a compound of Formula XV:
[0920] RPG2
[0921] o
[0922] HO YiRr
[0923] Xp
[0924]
[0925] R2(XV),
[0926] or a pharmaceutically acceptable salt thereof,
[0927] wherein:
[0928] R2is Cl, I, or pseudohalo; and
[0929] RPG2is an amine protecting group;
[0930] comprising hydrolyzing a compound of Formula IV:
[0931] RPG2
[0932] o
[0933] /
[0934] X)
[0935]
[0936] R2(IV),
[0937] wherein:
[0938] RCAis a chiral auxiliary;
[0939] to form the compound of Formula V.
[0940] In another aspect, provided herein is a process for preparing a compound of Formula IV:
[0941] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0942] RPG2
[0943]
[0944] wherein:
[0945] R2is Cl, I, or pseudohalo;
[0946] RCAis a chiral auxiliary; and
[0947] RPG2is an amine protecting group;
[0948] the process comprising reacting a compound of Formula III:
[0949] RPG2
[0950] O RGA^^ / (in),
[0951] with a compound of Formula XVI:
[0952]
[0953] wherein:
[0954] R5is halo or pseudohalo;
[0955] to form the compound of Formula VI.
[0956] In still another embodiment, Formula III is alkylated to form Formula IV.
[0957] In an aspect, provided herein is a process for preparing a compound of Formula III:
[0958] RPG2
[0959] O
[0960]
[0961] (in),
[0962] or a pharmaceutically acceptable salt thereof,
[0963] wherein:
[0964] RCAis a chiral auxiliary; and
[0965] RPG2is an amine protecting group;
[0966] wherein the process comprises forming an amide bond by coupling a compound of Formula XVII:
[0967] RPG2
[0968] O <N
[0969]
[0970] (XVII),
[0971] with an oxazolidinone derivative
[0972] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0973] to form the compound of Formula III.
[0974] In an embodiment, the oxazolidinone derivative has the following structure:
[0975] In another embodiment, the chiral auxiliary is:
[0976]
[0977] O
[0978] In an aspect, provided herein is a process for preparing a compound of Formula XIV:
[0979] RPG2
[0980]
[0981] (XIV),
[0982] or a pharmaceutically acceptable salt thereof,
[0983] wherein:
[0984] RPG1is a carboxylic acid protecting group; and
[0985] RPG2is an amine protecting group;
[0986] wherein the process comprises protecting a compound of Formula XIV-CN:
[0987] RPG2
[0988] /
[0989]
[0990] (XIV-CN),
[0991] to form the compound of Formula IV.
[0992] In another aspect, provided herein is a process for preparing a compound of Formula XIV-CN:
[0993] RPG2
[0994] /
[0995]
[0996] (XIV-CN),
[0997] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[0998] wherein:
[0999] RPG2is an amine protecting group;
[1000] wherein the process comprises hydrolyzing a compound of Formula XV-CN:
[1001] RPG2
[1002]
[1003] (XV-CN),
[1004] wherein:
[1005] RCAis a chiral auxiliary;
[1006] to form the compound of Formula V.
[1007] In another aspect, provided herein is a process for preparing a compound of Formula XVI-CN:
[1008] / RPG2
[1009]
[1010] (XVI-CN),
[1011] or a pharmaceutically acceptable salt thereof,
[1012] wherein:
[1013] RCAis a chiral auxiliary; and
[1014] RPG2is an amine protecting group;
[1015] wherein the process comprises reacting a compound of Formula III:
[1016] RPG2
[1017] O N RCA^(R)
[1018]
[1019] with a compound of Formula VIII:
[1020] CN
[1021] Br
[1022]
[1023] (XVI-CN),
[1024] to form the compound of Formula XVI-CN.
[1025] In an aspect, provided herein is a process for preparing a compound of Formula XVII:
[1026] 65
[1027] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1028]
[1029] (XVII),
[1030] or a pharmaceutically acceptable salt thereof,
[1031] wherein:
[1032] RPG1is a carboxylic acid protecting group; and
[1033] RPG2is an amine protecting group;
[1034] wherein the process comprises converting the compound of Formula XVIII:
[1035]
[1036] to form the compound of Formula XVII-CN.
[1037] In an embodiment, the compound of Formula X is nitrilized to form a compound of Formula (XVII-CN)
[1038] In an aspect, provided herein is a process for preparing a compound of Formula XIX:
[1039]
[1040] (XIX),
[1041] or a pharmaceutically acceptable salt thereof,
[1042] wherein:
[1043] RPG1is a carboxylic acid protecting group; and
[1044] RPG2is an amine protecting group;
[1045] wherein the process comprises converting a compound of Formula XX:
[1046] 66
[1047] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1048]
[1049] (XX),
[1050] In an aspect, provided herein is a process for preparing a compound of Formula XXI:
[1051]
[1052] (XXI),
[1053] or a pharmaceutically acceptable salt thereof,
[1054] wherein:
[1055] RPG1is a carboxylic acid protecting group; and
[1056] RPG2is an amine protecting group;
[1057] the process comprises converting a compound of Formula XXII:
[1058]
[1059] (XXII),
[1060] wherein:
[1061] X is a counterion;
[1062] to form the compound of Formula lll-A.
[1063] In an embodiment, the process for preparing a compound of Formula XXI comprises performing a nitrilation reaction on a compound of Formula XXII.
[1064] In an aspect, provided herein is a process for preparing a compound of Formula XXII:
[1065] 67
[1066] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1067]
[1068] (XXII),
[1069] or a pharmaceutically acceptable salt thereof,
[1070] wherein:
[1071] RPGI is a carboxylic acid protecting group;
[1072] RPG2 is an amine protecting group; and
[1073] X is a counterion;
[1074] wherein the process comprises converting a compound of Formula XXIII:
[1075]
[1076] (XXIII),
[1077] to form the compound of Formula XII.
[1078] In an embodiment, the process for preparing a compound of Formula XXII comprises performing a diazotization reaction on a compound of Formula XXIII to form a compound of Formula XXII.
[1079] In an aspect, provided herein is a process for preparing a compound of Formula XXIV:
[1080]
[1081] (XXIV),
[1082] or a pharmaceutically acceptable salt thereof,
[1083] wherein:
[1084] RPGI is a carboxylic acid protecting group; and
[1085] RPG2 is an amine protecting group;
[1086] wherein the process comprises converting a compound of Formula XXIV:
[1087] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1088] RpG2
[1089] 0
[1090] RPG1_O-^Y^- /
[1091] u
[1092]
[1093] NHRPG3(XXIV),
[1094] wherein:
[1095] RPG3is an amine protecting group;
[1096] to form the compound of Formula XIII.
[1097] In another aspect, provided herein is a process for preparing a compound of Formula XXV:
[1098]
[1099] (XXV),
[1100] or a pharmaceutically acceptable salt thereof,
[1101] wherein:
[1102] RPGI is a carboxylic acid protecting group;
[1103] RPG2 is an amine protecting group; and
[1104] RPG3is an amine protecting group;
[1105] wherein the process comprises reacting a compound of Formula III:
[1106] RPG2
[1107] O ^N'
[1108] RCA^^XX^ / (| | |),
[1109]
[1110] with a compound of Formula VIII:
[1111]
[1112] wherein:
[1113] R1is NHRPG3
[1114] to form the compound of Formula XIV.
[1115] In an aspect, provided herein is a process for preparing a compound of Formula VII:
[1116] 69
[1117] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1118] RPG2
[1119]
[1120] or a pharmaceutically acceptable salt thereof,
[1121] wherein:
[1122] RPG2is an amine protecting group;
[1123] wherein the process comprises coupling a compound of Formula IX:
[1124] RPG2
[1125] O
[1126]
[1127] (ix),
[1128] with a compound having the structure of:
[1129]
[1130] to form the compound of Formula VII. In an embodiment of any one of the above processes, RPG3is a 9-fluorenylmethyloxycarbonyl (Fmoc) protecting group.
[1131] In another embodiment of any one of the above processes, RPG2is a tertbutyloxycarbonyl (Boc) protecting group.
[1132] In yet another embodiment of any one of the above processes RPG1is a tert-butyl (tBu) protecting group.
[1133] In another aspect provided herein, is a process for preparing a compound of Formula (IV), Formula (Xlll-A), or Formula (I*), wherein:
[1134] (1) the compound prepared is a compound of Formula (I*):
[1135] RpG2
[1136]
[1137] rB(i*);
[1138] or a pharmaceutically acceptable salt thereof;
[1139] wherein:
[1140] RBis H, -C1-3 alkyl-Ce-w aryl, or-Ci-3 alkyl-Ce-w carbocyclyl, wherein -C1-3 alkyl-Ce-w aryl is optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -C(O)H, -CC>2-(Ci-6 alkyl), 5- to 7-membered heterocycloalkyl, -CH2NR2, - CH2OR, -C(O)R, -CN, -N2X, or-NR2; wherein -C1-3 alkyl-Ce-w carbocyclyl is optionally 70
[1141] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1142] substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, - CO2R, -CN, -N2X, or-NR2;
[1143] each R is independently H or C1-3 alkyl;
[1144] X is a counterion; and
[1145] RAis RCAor RD;
[1146] wherein:
[1147] RCAis a chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative; and
[1148] RDis C1-6 heteroalkyl or C1-3 heteroalkyl-Ce-w aryl; wherein each are optionally substituted with one or more of halo, C1-3 alkyl, or C1-3 alkoxy; and
[1149] the process comprises palladium-catalyzed carbonylation of a compound of Formula Xlll-A:
[1150] RPG2
[1151] S
[1152]
[1153] >2
[1154] (Xlll-A),
[1155] or a pharmaceutically acceptable salt thereof,
[1156] wherein:
[1157] R2is halo, pseudohalo, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-3 haloalkyl, - CH2NR2, -CH2O-PG, -CH2OR, -C(O)R, -CN, -N2X, or-NR2;
[1158] X is counterion;
[1159] each R is independently H or C1-3 alkyl;
[1160] PG is a protecting group;
[1161] RPG2is a pyrrolidine protecting group; and
[1162] R4is C1-6 alkyl, C6-i2aryl, or -C1-3 alkyl-C6-i2aryl; wherein R4is optionally further substituted by halo or C1-6 alkoxy;
[1163] to form the compound of Formula I*;
[1164] (2) the compound prepared is a compound of Formula Xlll-A:
[1165] RPG2
[1166] S
[1167] >2
[1168]
[1169] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1170] and the process comprises thioesterification of a compound of Formula IV:
[1171] RPG2
[1172]
[1173] or a pharmaceutically acceptable salt thereof;
[1174] wherein:
[1175] RCAis a chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative.
[1176] to form the compound of Formula Xlll-A; and
[1177] (3) the compound prepared is a compound of Formula IV:
[1178] RPG2
[1179]
[1180] or a pharmaceutically acceptable salt thereof;
[1181] and the process comprises asymmetric alkylation of a compound of Formula III:
[1182] RPG2
[1183] O RCA-^^-Z(| ||)J
[1184]
[1185] with a compound of Formula XVI:
[1186]
[1187] wherein:
[1188] R5is halo or pseudohalo;
[1189] to form the compound of Formula (IV).
[1190] In another aspect provided herein, is a process for preparing a compound of Formula (IV), Formula (Xlll-A), or Formula (I*), wherein:
[1191] (1) the compound prepared is a compound of Formula (I*):
[1192] 72
[1193] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1194] RPG2
[1195] RA
[1196]
[1197] RB
[1198] or a pharmaceutically acceptable salt thereof;
[1199] wherein:
[1200] RPG2is a pyrrolidine protecting group;
[1201] RBis -Ci alkyl-Ce aryl substituted with -C(O)H;
[1202] RAis RD, wherein RDis C2 heteroalkyl-Cearyl optionally substituted with one or more of halo, or C1-3 alkoxy; and the hetero group is sulfur; and
[1203] the process comprises palladium-catalyzed carbonylation of a compound of Formula Xlll-A:
[1204] RPG2
[1205]
[1206] (Xlll-A),
[1207] or a pharmaceutically acceptable salt thereof,
[1208] wherein:
[1209] R2is halo, pseudohalo, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-3 haloalkyl, - CH2NR2, -CH2O-PG, -CH2OR, -C(O)R, -CN, -N2X, or-NR2;
[1210] X is counterion;
[1211] each R is independently H or C1-3 alkyl;
[1212] PG is a protecting group;
[1213] RPG2is a pyrrolidine protecting group; and
[1214] R4is C1-6 alkyl, C6-i2aryl, or -C1-3 alkyl-C6-i2aryl; wherein R4is optionally further substituted by halo or C1-6 alkoxy;
[1215] to form the compound of Formula I*;
[1216] (2) the compound prepared is a compound of Formula Xlll-A:
[1217] RPG2
[1218]
[1219] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1220] and the process comprises thioesterification of a compound of Formula IV:
[1221] RPG2
[1222]
[1223] or a pharmaceutically acceptable salt thereof;
[1224] wherein:
[1225] RCAis a chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative.
[1226] to form the compound of Formula Xlll-A; and
[1227] (3) the compound prepared is a compound of Formula IV:
[1228] RPG2
[1229]
[1230] or a pharmaceutically acceptable salt thereof;
[1231] and the process comprises asymmetric alkylation of a compound of Formula III:
[1232] RPG2
[1233] O RCA-^^-Z(| ||)J
[1234]
[1235] with a compound of Formula XVI:
[1236]
[1237] wherein:
[1238] R5is halo or pseudohalo;
[1239] to form the compound of Formula (IV).
[1240] In some embodiments, in the process for preparing compounds of Formula (IV), RDis C1-3 heteroalkyl-Ce-w aryl, wherein the Ce- aryl is optionally substituted with one or more substituents selected from halo, C1-3 alkyl, and C1-3 alkoxy.
[1241] In some embodiments, the process for preparing compounds of Formula (IV) is a process wherein:
[1242] RPG2is a pyrrolidine protecting group;
[1243] 74
[1244] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1245] RBis -Ci alkyl-Ce aryl substituted with -C(O)H;
[1246] RAis RD, wherein RDis C2 heteroalkyl-Cearyl optionally substituted with one or more of halo, or C1-3 alkoxy; and the hetero group is sulfur
[1247] In another aspect provided herein, is a process for preparing Compound (1):
[1248] Boc
[1249] O
[1250] < 'Y s
[1251]
[1252] (1),
[1253] or a salt thereof,
[1254] the process comprising:
[1255] (a) reacting Compound (4):
[1256] Boc
[1257] o orN'
[1258]
[1259] ph (4),
[1260] of a salt thereof, with Compound (5):
[1261] Br^Q
[1262]
[1263] Br (5),
[1264] and at least one base to produce Compound (3):
[1265]
[1266] or a salt thereof;
[1267] (b) reacting Compound (3), or a salt thereof, with Compound (6):
[1268] SH
[1269]
[1270] (6),
[1271] or a salt thereof, to produce Compound (2):
[1272] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1273]
[1274] or a salt thereof;
[1275] (c) reacting Compound (2) with a palladium catalyst and a carbon monoxide source to produce Compound (1).
[1276] In another aspect provided herein, is a process for preparing compounds of Formula (Xlll-A):
[1277] (1) the compound prepared is a compound of Formula (Xlll-A):
[1278] RPG2
[1279]
[1280] (Xlll-A),
[1281] or a pharmaceutically acceptable salt thereof,
[1282] wherein:
[1283] R2is -CH2NR2;
[1284] each R is independently H or C1-3 alkyl;
[1285] PG is a protecting group;
[1286] RPG2is a pyrrolidine protecting group; and
[1287] R4is C1-6 alkyl, C6-i2aryl, or -C1-3 alkyl-C6-i2aryl; wherein the -C1-3 alkyl-Ce- i2aryl is optionally substituted by C2-6 alkoxy;
[1288] the process comprises reduction of a compound of Formula (Xlll-A) wherein R2is -CN to form the compound of Formula (Xlll-A) wherein R2is -CH2NR2;
[1289] (2) the compound prepared is a compound of Formula (Xlll-A):
[1290] RPG2
[1291]
[1292] (Xlll-A),
[1293] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1294] wherein:
[1295] R2is -CN;
[1296] the process comprises transnitrilation of a compound of Formula (Xlll-A) wherein R2is halo to form the compound of Formula (Xlll-A) wherein R2is -CN.
[1297] In another aspect provided herein, is a process for preparing a compound of Formula (Xlll-A) wherein:
[1298] (1) the compound prepared is a compound of Formula (Xlll-A):
[1299] RPG2
[1300]
[1301] (Xlll-A),
[1302] or a pharmaceutically acceptable salt thereof,
[1303] wherein:
[1304] R2is -CH2NR2;
[1305] each R is independently H or C1-3 alkyl;
[1306] PG is a protecting group;
[1307] RPG2is a pyrrolidine protecting group; and
[1308] R4is C1-3 alkyl, Ce-i2aryl, or -C1-3 alkyl-C6-i2aryl; wherein the -C1-3 alkyl-Ce- i2aryl is optionally substituted by C2-6 alkoxy;
[1309] the process comprises reduction of a compound of Formula (Xlll-A) wherein R2is -CN to form the compound of Formula (Xlll-A) wherein R2is -CH2NR2;
[1310] (2) the compound prepared is a compound of Formula (Xlll-A):
[1311] RPG2
[1312] /
[1313]
[1314] (Xlll-A),
[1315] wherein:
[1316] R2is -CN;
[1317] the process comprises transnitrilation of a compound of Formula (Xlll-A) wherein R2is halo to form the compound of Formula (Xlll-A) wherein R2is -CN.
[1318] In some embodiments, provided herein is a process for preparing Compound 1:
[1319] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1320]
[1321] (1);
[1322] or a salt thereof;
[1323] wherein the process comprises the step of subjecting Formula (XI I l-p1 );
[1324]
[1325] (Xlll-p1),
[1326] or a salt thereof, wherein R2is halo or pseudohalo;
[1327] to palladium catalyzed carbonylation conditions produce Compound 1.
[1328] In some embodiments, provided herein is a process for preparing Compound 7:
[1329] / Boc
[1330]
[1331] or a salt thereof;
[1332] wherein the process comprises the step of subjecting a compound of Formula (XIII- P2):
[1333] RPG2
[1334]
[1335] R2(Xlll-p2);
[1336] or a salt thereof, wherein R2is halo or pseudohalo;
[1337] to palladium catalyzed carbonylation conditions to produce Compound 7.
[1338] 78
[1339] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1340] In some embodiments, provided herein is a process for preparing a compound of Formula (Xlll-p1):
[1341]
[1342] (Xlll-p1);
[1343] or a salt thereof, wherein:
[1344] RPG2is a pyrrolidine protecting group;
[1345] R2is halo or pseudohalo; and
[1346] R6is halo or C1-5 alkoxy;
[1347] wherein the process comprises the step of reacting a compound of Formula (IV-A):
[1348] RPG2
[1349]
[1350] (IV-A);
[1351] or a salt thereof, wherein:
[1352] R2is halo or pseudohalo;
[1353] RA1and RA2are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RA1and RA2are each further optionally substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, or -OR; and
[1354] each R is independently H or C1-3 alkyl;
[1355] with a benzyl mercaptan to produce a compound of Formula (XI I l-p1 ).
[1356] In some embodiments, provided herein is a process for preparing a compound of Formula (Xlll-p1):
[1357]
[1358] (Xlll-p1);
[1359] or a salt thereof, wherein:
[1360] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1361] RPG2is a pyrrolidine protecting group;
[1362] R2is halo or pseudohalo; and
[1363] R6is halo or C1-5 alkoxy;wherein the process comprises the step of reacting a compound of Formula IV-B:
[1364] RPG2
[1365]
[1366] R2(IV-B),
[1367] or a salt thereof, wherein:
[1368] R2is halo or pseudohalo;
[1369] RB1, RB2, and RB3are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RB1, RB2, and RB3are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, - OR; and
[1370] each R is independently H or C1-3 alkyl;
[1371] with benzyl mercaptan to produce a compound of Formula (XII l-p1).
[1372] In some embodiments, provided herein is a process for a compound of Formula (XIII-P1):
[1373]
[1374] (Xlll-p1);
[1375] or a salt thereof, wherein:
[1376] RPG2is a pyrrolidine protecting group;
[1377] R2is halo or pseudohalo; and
[1378] R6is halo or C1-5 alkoxy;wherein the process comprises the step of reacting a compound of Formula IV-B-a:
[1379] 80
[1380] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1381] Ph— N
[1382] RB1
[1383]
[1384] (IV-B-a),
[1385] or a salt thereof, wherein:
[1386] R2is halo or pseudohalo;
[1387] RB1is C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, -CN, -NR2, -OR; and
[1388] each R is independently H or C1-3 alkyl;
[1389] with benzyl mercaptan to produce a compound of Formula (XII l-p1).
[1390] In some embodiments, provided herein is a process for preparing a compound of Formula (Xlll-p1):
[1391]
[1392] (Xlll-p1);
[1393] or a salt thereof, wherein:
[1394] RPG2is a pyrrolidine protecting group;
[1395] R2is halo or pseudohalo; and
[1396] R6is halo or C1-5 alkoxy;
[1397] wherein the process comprises the step of reacting a compound of Formula lll-E:
[1398]
[1399] or a salt thereof, wherein:
[1400] RPG2is a pyrrolidine protecting group;
[1401] RE1is C1-3 alkyl, C6-12 aryl, or 5-10 membered heteroaryl; and RE2is C1-3 alkyl, C6-12 aryl, or 5-10 membered heteroaryl;
[1402] with benzyl mercaptan to produce a compound of Formula (XII l-p1).
[1403] 81
[1404] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1405] In some embodiments, provided herein is a process for preparing a compound of Formula (XII l-p2):
[1406] RPG2
[1407]
[1408] R2(Xlll-p2);
[1409] or a salt thereof, wherein R2is halo or pseudohalo;
[1410] wherein the process comprises the step of reacting a compound of Formula (IV-A):
[1411] RPG2
[1412]
[1413] R2(IV-A);
[1414] or a salt thereof, wherein:
[1415] R2is halo or pseudohalo;
[1416] RA1and RA2are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RA1and RA2are each further optionally substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, or -OR; and
[1417] each R is independently H or C1-3 alkyl;
[1418] with terf-butylthiol to produce a compound of Formula (XI I l-p2).
[1419] In some embodiments, provided herein is a process for preparing a compound of Formula (XII l-p2):
[1420] RPG2
[1421]
[1422] R2(Xlll-p2);
[1423] or a salt thereof, wherein R2is halo or pseudohalo;
[1424] wherein the process comprises the step of reacting Compound 11:
[1425] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1426]
[1427] or a salt thereof, wherein:
[1428] R2is halo or pseudohalo;
[1429] with terf-butylthiol to produce a compound of Formula (XI I l-p2).
[1430] In some embodiments, provided herein is a process for preparing a compound of Formula (XII l-p2):
[1431]
[1432] R2(Xlll-p2);
[1433] or a salt thereof, wherein R2is halo or pseudohalo;
[1434] wherein the process comprises the step of reacting a compound of Formula IV-B:
[1435] RPG2
[1436]
[1437] R2(IV-B),
[1438] or a salt thereof, wherein:
[1439] R2is halo or pseudohalo;
[1440] RB1, RB2, and RB3are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RB1, RB2, and RB3are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, - OR; and
[1441] each R is independently H or C1-3 alkyl;
[1442] with terf-butylthiol to produce a compound of Formula XI I l-p2.
[1443] In some embodiments, provided herein is a process for preparing a compound of Formula (XII l-p2):
[1444] 83
[1445] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1446] RPG2
[1447]
[1448] R2(Xlll-p2);
[1449] or a salt thereof, wherein R2is halo or pseudohalo;
[1450] wherein the process comprises the step of reacting a compound of Formula IV-B-a:
[1451] RPG2
[1452]
[1453] R2(IV-B-a),
[1454] or a salt thereof, wherein:
[1455] R2is halo or pseudohalo;
[1456] RB1is C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, -CN, -NR2, -OR; and
[1457] each R is independently H or C1-3 alkyl;
[1458] with terf-butylthiol to produce a compound of Formula XI I l-p2.
[1459] In some embodiments, provided herein is a process for preparing a compound of Formula (XII l-p2):
[1460] RPG2
[1461]
[1462] R2(Xlll-p2);
[1463] or a salt thereof, wherein R2is halo or pseudohalo;
[1464] wherein the process comprises the step of reacting Compound 12:
[1465] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1466]
[1467] or a salt thereof, wherein:
[1468] R2is halo or pseudohalo;
[1469] with terf-butylthiol to produce a compound of Formula XI I l-p2.
[1470] In some embodiments, provided herein is a process for preparing a compound of Formula (XII l-p2):
[1471]
[1472] R2(Xlll-p2);
[1473] or a salt thereof, wherein R2is halo or pseudohalo;
[1474] wherein the process comprises the step of reacting a compound of Formula lll-E:
[1475]
[1476] or a salt thereof, wherein:
[1477] RPG2is a pyrrolidine protecting group;
[1478] RE1is C1-3 alkyl, C6-12 aryl, or 5-10 membered heteroaryl; and RE2is C1-3 alkyl, C6-12 aryl, or 5-10 membered heteroaryl;
[1479] with terf-butylthiol to produce a compound of Formula XI I l-p2.
[1480] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1481] In another aspect, provided herein is a compound selected from the group consisting
[1482]
[1483] and
[1484]
[1485] OTs ; or a pharmaceutically acceptable salt thereof.
[1486] In another aspect, provided herein is a compound selected from the group consisting of:
[1487] / Boc
[1488]
[1489] and or a pharmaceutically acceptable salt thereof.
[1490] 86
[1491] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1492] It is further appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment (while the embodiments are intended to be combined as if written in multiply dependent form). Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable sub-combination. Thus, it is contemplated as features described as embodiments of the compounds of Formula I can be combined in any suitable combination.
[1493] EXAMPLES
[1494] The disclosure is further illustrated by the following examples, which should not be construed as further limiting. The practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of organic synthesis, cell biology, cell culture, and molecular biology, which are within the skill of the art.
[1495] Example 1:
[1496]
[1497] step A3 step A4 step A5 hydrolysis protection nitrilation
[1498]
[1499] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1500] step A6 (a) imination
[1501]
[1502] step A3 step A4 step A5 hydrolysis
[1503]
[1504] protection transnitrilation
[1505]
[1506]
[1507] l-5a
[1508]
[1509] 82684654v1Attorney Docket No.: 777812: CAT-036PC
[1510] step A6 (a) imination
[1511]
[1512] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1513] Example 3:
[1514]
[1515] Yb(0Tf)3, MeOH, TMOF Zn(CN)2; Pd(pph3)4 then LiOH, H2O 2-MeTHF, KHSO4DMF: N2: 120oC: 2h step B3 step B4 step B5 hydrolysis protection transnitrilation
[1516]
[1517] l-4b
[1518] Ni, H2, MeOH, rt step B6 (a) amination
[1519]
[1520] l-6b-INT l-7b
[1521] 90
[1522] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1523] Example 4:
[1524]
[1525] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1526] Example 5:
[1527]
[1528] Yb(0Tf)3, MeOH, TMOF
[1529] then LiOH, H2O
[1530] step B3 step B4 hydrolysis protection
[1531]
[1532] l-4c l-6c
[1533] Ni, H2, MeOH, rt step B6 (a)
[1534]
[1535] l-6b-INT
[1536]
[1537] 92
[1538] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1539] Example 6:
[1540] Example 7:
[1541]
[1542] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1543] Route 8.3a
[1544] Route 8.3b
[1545]
[1546] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1547] Route 8.3c
[1548] Route 8.3d
[1549]
[1550] Example 9:
[1551] Route 9.1
[1552]
[1553] 82684654v1Attorney Docket No.: 777812: CAT-036PC
[1554] Route 9.2
[1555]
[1556] Example 10:
[1557] Route 10.1
[1558] R4-OH
[1559] Pd-catalysed carbonylation
[1560]
[1561] 82684654v1Attorney Docket No.: 777812: CAT-036PC
[1562] Route 10.1.1
[1563] Route 10.1.2
[1564]
[1565] Route 10.1.3
[1566] Route 10.1.4
[1567]
[1568] Route 10.1.5
[1569] Route 10.1.6
[1570]
[1571] 97
[1572] 82684654v1Atorney Docket No.: 777812: CAT-036PC Route 10.1.7
[1573] Route 10.2
[1574] transnitrilation reduction
[1575]
[1576] Route 10.3
[1577] deprotection
[1578]
[1579] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1580] Route 10.3.1
[1581] Route 10.4
[1582] transnitrilation
[1583] Route 10.4.2
[1584]
[1585] 99
[1586] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1587] Route 10.4.3
[1588] Example 11 : Route 11.1 Route 11.1.1
[1589] Route 11.1.1b
[1590]
[1591] 100
[1592] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1593] Route 11.1.1c
[1594] Route 11.1.1f
[1595] Route 11.1.1g
[1596]
[1597] 101
[1598] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1599] Route 11.1.2
[1600] Pd-catalysed carbonylation
[1601] Route 11.1.2a
[1602] Pd-catalyzed carbonylation
[1603]
[1604] Route 11.2
[1605] Route 11.2.1
[1606] transnitrilation reduction
[1607]
[1608] Route 11.2.2
[1609]
[1610] 102
[1611] 82684654v1Attorney Docket No.: 777812: CAT-036PC Route 11.2.2a
[1612] Route 11.2.2b
[1613]
[1614] Route 11.3
[1615] deprotection
[1616]
[1617] 103
[1618] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1619] Route 11.3.1
[1620] Route 11.3.2
[1621]
[1622] 104
[1623] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1624] Various modifications of the disclosure, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference, including without limitation all patent, patent applications, and publications, cited in the present application is incorporated herein by reference in its entirety.
[1625] 105
[1626] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1627] EMBODIMENTS
[1628] The following constitute particularly numbered embodiments of the present invention: Embodiment 1. A compound of Formula I*:
[1629] RPG2
[1630]
[1631] rB(I*);
[1632] or a pharmaceutically acceptable salt thereof;
[1633] wherein:
[1634] RBis H, -C1-3 alkyl-Ce-w aryl, optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -C(O)H, -CO2-(Ci-6 alkyl), 5- to 7-membered heterocycloalkyl, -CH2NR2, -CH2OR, -C(O)R, -CN, -N2X, or-NR2; -C1-3 alkyl-Ce-w carbocyclyl, optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;
[1635] each R is independently H or C1-3 alkyl;
[1636] X is a counterion; and
[1637] RAis RCAor RD;
[1638] wherein:
[1639] RCAis a chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative; and
[1640] RDis C1-3 heteroal kyl-Ce-w aryl, optionally substituted with one or more of halo, C1-3 alkyl, or C1-3 alkoxy.
[1641] Embodiment 2. The compound of numbered embodiment 1 , wherein the compound of Formula I* is a compound of Formula I:
[1642] RPG2
[1643] O
[1644]
[1645] RB(I);
[1646] or a pharmaceutically acceptable salt thereof;
[1647] wherein:
[1648] RBis H, -C1-3 alkyl-Ce-w aryl, optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -C(O)H, -CC>2-(Ci-6 alkyl), 5- to 7-membered heterocycloalkyl, -CH2NR2, -CH2OR, -C(O)R, -CN, -N2X, or-NR2; -C1-3 alkyl-Ce-w carbocyclyl, optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;
[1649] each R is independently H or C1-3 alkyl;
[1650] and
[1651] RAis RCAor RD;
[1652] 106
[1653] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1654] wherein:
[1655] RCAis a chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative; and
[1656] RDis C1-3 heteroalkyl-Ce- aryl, optionally substituted with one or more of halo, C1-3 alkyl, or C1-3 alkoxy.
[1657] Embodiment 3. The compound of numbered embodiment 2, wherein the compound of Formula I is a compound of Formula II:
[1658] RPG2
[1659]
[1660] RB(II),
[1661] or a pharmaceutically acceptable salt thereof;
[1662] wherein:
[1663] RBis H, -C1-3 alkyl-Ce- aryl, optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NR2, -CH2OR, -C(O)R, -CN, -N2X, or-NR2; -C1.3 alkyl-C6-io carbocyclyl, optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;
[1664] X is a counterion;
[1665] each R is independently H or C1-3 alkyl;
[1666] RPG2is a pyrrolidine protecting group; and
[1667] RCAis a chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative.
[1668] Embodiment 4. The compound of numbered embodiment 2, wherein the compound of Formula II is a compound of Formula III:
[1669] RPG2
[1670] O RCA-V / "^Z(|||)J
[1671]
[1672] wherein:
[1673] RPG2is a pyrrolidine protecting group; and
[1674] RCAis a chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative.
[1675] 107
[1676] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1677] Embodiment 5. The compound of numbered embodiment 4, wherein the compound of Formula III is a compound of Formula lll-A:
[1678]
[1679] (IH-A),
[1680] wherein:
[1681] RPG2is a pyrrolidine protecting group;
[1682] RA1and RA2are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RA1and RA2are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[1683] each R is independently H or C1-3 alkyl.
[1684] Embodiment 6. The compound of numbered embodiment 4, wherein the compound of Formula III is a compound of Formula lll-B:
[1685] RPG2
[1686]
[1687] wherein:
[1688] RPG2is a pyrrolidine protecting group;
[1689] RB1, RB2, and RB3are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RB1, RB2, and RB3are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[1690] each R is independently H or C1-3 alkyl.
[1691] Embodiment 7. The compound of numbered embodiment 4, wherein the compound of Formula III is a compound of Formula lll-C:
[1692]
[1693] wherein:
[1694] RPG2is a pyrrolidine protecting group;
[1695] 108
[1696] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1697] RC1, RC2, and RC3are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RC1, RC2, and RC3are each further optionally substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[1698] each R is independently H or C1-3 alkyl.
[1699] Embodiment 8. The compound of numbered embodiment 4, wherein the compound of Formula III is a compound of Formula lll-D:
[1700]
[1701] (Hl-D),
[1702] or a pharmaceutically acceptable salt thereof;
[1703] wherein:
[1704] RPG2is a pyrrolidine protecting group.
[1705] Embodiment 9. A compound of Formula lll-E:
[1706]
[1707] or a pharmaceutically acceptable salt thereof;
[1708] wherein:
[1709] RPG2is a pyrrolidine protecting group;
[1710] RE1and RE2are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RE1and RE2are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR;
[1711] RE3and RE4are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RE1and RE2are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[1712] each R is independently H or C1-3 alkyl.
[1713] 109
[1714] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1715] Embodiment 10. The compound of numbered embodiment 2, wherein the compound of Formula II is a compound of Formula IV:
[1716] RPG2
[1717]
[1718] or a pharmaceutically acceptable salt thereof;
[1719] wherein:
[1720] R2is halo, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-3 haloalkyl, -CH2NR2, -CH2O-PG, -CH2OR, -C(O)R, -CN, -N2X, or -NR2; -C1-3 alkyl-Ce-w carbocyclyl, optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;
[1721] X is counterion;
[1722] each R is independently H or C1-3 alkyl;
[1723] PG is a protecting group;
[1724] RPG2is a pyrrolidine protecting group; and
[1725] RCAis a chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative.
[1726] Embodiment 11. The compound of numbered embodiment 10, wherein the compound of Formula IV is a compound of Formula IV-A:
[1727] RPG2
[1728]
[1729] R2(IV-A),
[1730] wherein:
[1731] R2is halo, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-3 haloalkyl, -CH2NR2, -CH2O-PG, -CH2OR, -C(O)R, -CN, -N2X, or -NR2; -C1-3 alkyl-Ce-w carbocyclyl, optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;
[1732] X is counterion;
[1733] PG is a protecting group;
[1734] RPG2is a pyrrolidine protecting group;
[1735] 110
[1736] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1737] RA1and RA2are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RA1and RA2are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[1738] each R is independently H or C1-3 alkyl.
[1739] Embodiment 12. The compound of numbered embodiment 11, wherein the compound of Formula IV-A is a compound of Formula IV-A2:
[1740] RPG2
[1741] N
[1742] y N
[1743] OH Me
[1744]
[1745] (IV-A2),
[1746] wherein:
[1747] RPG2is a pyrrolidine protecting group;
[1748] RA1and RA2are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RA1and RA2are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[1749] each R is independently H or C1-3 alkyl.
[1750] Embodiment 13. The compound of numbered embodiment 10, wherein the compound of Formula IV is a compound of Formula IV-B:
[1751] RPG2
[1752] N
[1753] RB1
[1754] >2
[1755]
[1756] wherein:
[1757] R2is halo, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-3 haloalkyl, -CH2NR2, -CH2O-PG, -CH2OR, -C(O)R, -CN, -N2X, or -NR2; -C1-3 alkyl-Ce- carbocyclyl, optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;
[1758] X is counterion;
[1759] PG is a protecting group;
[1760] RPG2is a pyrrolidine protecting group;
[1761] 111
[1762] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1763] RB1, R , and RB3are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RB1, RB2, and RB3are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[1764] each R is independently H or C1-3 alkyl.
[1765] Embodiment 14. The compound of numbered embodiment 13, wherein the compound of Formula IV-B is a compound of Formula IV-B2:
[1766] RPG2
[1767] N
[1768] B2
[1769] RB1
[1770]
[1771] (IV-B2),
[1772] wherein:
[1773] RPG2is a pyrrolidine protecting group;
[1774] RB1, RB2, and RB3are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RB1, RB2, and RB3are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[1775] each R is independently H or C1-3 alkyl.
[1776] Embodiment 15. The compound of numbered embodiment 10, wherein the compound of Formula IV is a compound of Formula IV-C:
[1777] RPG2
[1778] RC2 RC3O N
[1779] RC1
[1780]
[1781] (IV-C),
[1782] wherein:
[1783] R2is halo, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-3 haloalkyl, -CH2NR2, -CH2O-PG, -CH2OR, -C(O)R, -CN, -N2X, or -NR2; -C1-3 alkyl-Ce- carbocyclyl, optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;
[1784] X is counterion;
[1785] PG is a protecting group;
[1786] RPG2is a pyrrolidine protecting group;
[1787] 112
[1788] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1789] RC1, R , and RC3are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RC1, RC2, and RC3are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[1790] each R is independently H or C1-3 alkyl.
[1791] Embodiment 16. The compound of numbered embodiment 15, wherein the compound of Formula IV-C is a compound of Formula IV-C2:
[1792] RPG2
[1793] RC2 RC3On.
[1794] rC1Y'j
[1795]
[1796] X) (IV-C2),
[1797] wherein:
[1798] RPG2is a pyrrolidine protecting group;
[1799] RC1, RC2, and RC3are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RC1, RC2, and RC3are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[1800] each R is independently H or C1-3 alkyl.
[1801] Embodiment 17. The compound of numbered embodiment 10, wherein the compound of Formula IV is a compound of Formula IV-D:
[1802] RpG2
[1803] O O
[1804] od f
[1805]
[1806] R2(IV-D),
[1807] or a pharmaceutically acceptable salt thereof;
[1808] wherein:
[1809] R2is halo, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-3 haloalkyl, -CH2NR2, -CH2O-PG, -CH2OR, -C(O)R, -CN, -N2X, or -NR2; -C1-3 alkyl-Ce- carbocyclyl, optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;
[1810] X is counterion;
[1811] PG is a protecting group;
[1812] 113
[1813] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1814] each R is independently H or C1-3 alkyl; and
[1815] RPG2is a pyrrolidine protecting group.
[1816] Embodiment 18. The compound of numbered embodiment 17, wherein the compound of Formula IV-D is a compound of Formula IV-D2:
[1817]
[1818] (IV-D2),
[1819] or a pharmaceutically acceptable salt thereof;
[1820] wherein:
[1821] RPG2is a pyrrolidine protecting group.
[1822] Embodiment 19. A compound of Formula (IV-E):
[1823]
[1824] or a pharmaceutically acceptable salt thereof;
[1825] wherein:
[1826] R2is halo, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-3 haloalkyl, -CH2NR2, -CH2O-PG, -CH2OR, -C(O)R, -CN, -N2X, or -NR2; -C1-3 alkyl-Ce- carbocyclyl, optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;
[1827] X is counterion;
[1828] PG is a protecting group;
[1829] each R is independently H or C1-3 alkyl;
[1830] RPG2is a pyrrolidine protecting group;
[1831] RE1and RE2are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RE1and RE2are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR;
[1832] 114
[1833] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1834] RE3and RE4are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RE1and RE2are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[1835] each R is independently H or C1-3 alkyl.
[1836] Embodiment 20. The compound of numbered embodiment 19, wherein the compound Formula (IV-E) is a compound of Formula (IV-E2):
[1837]
[1838] (IV-E2),
[1839] or a pharmaceutically acceptable salt thereof;
[1840] wherein:
[1841] RPG2is a pyrrolidine protecting group;
[1842] RE1and RE2are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RE1and RE2are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR;
[1843] RE3and RE4are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RE1and RE2are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; and
[1844] each R is independently H or C1-3 alkyl.
[1845] Embodiment 21. A compound of Formula V:
[1846]
[1847] (V),
[1848] or a pharmaceutically acceptable salt thereof,
[1849] wherein:
[1850] 115
[1851] 82684654v1Attorney Docket No.: 777812: CAT-036PC
[1852] R5is halo, or pseudohalo;
[1853] RPG1is a carboxylic acid protecting group;
[1854] RPG2is a pyrrolidine protecting group; and
[1855] RPG3is an amine protecting group.
[1856] Embodiment 22. A compound of Formula VI:
[1857] RPG2
[1858]
[1859] or a pharmaceutically acceptable salt thereof,
[1860] wherein:
[1861] RPG1is a carboxylic acid protecting group;
[1862] RPG2is a pyrrolidine protecting group;
[1863] RPG3is an amine protecting group;
[1864] RPG2is a pyrrolidine protecting group; and
[1865] RCAis a chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative.
[1866] Embodiment 23. A compound selected from the group consisting of:
[1867]
[1868] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1869] OH Me
[1870]
[1871] or a pharmaceutically acceptable salt thereof.
[1872] Embodiment 24. A compound selected from:
[1873]
[1874] 117
[1875] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1876]
[1877] or a pharmaceutically acceptable salt thereof.
[1878] Embodiment 25. A compound selected from:
[1879]
[1880] or a pharmaceutically acceptable salt thereof.
[1881] 118
[1882] 82684654v1Atorney Docket No.: 777812: CAT-036PC Embodiment 26. A compound selected from:
[1883]
[1884] or a pharmaceutically acceptable salt thereof.
[1885] Embodiment 27. A compound selected from:
[1886]
[1887] 119
[1888] 82684654v1Atorney Docket No.: 777812: CAT-036PC or a pharmaceutically acceptable salt thereof.
[1889] Embodiment 28. A compound selected from:
[1890]
[1891] or a pharmaceutically acceptable salt thereof.
[1892] Embodiment 29. A compound selected from:
[1893]
[1894] 120
[1895] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1896]
[1897] or a pharmaceutically acceptable salt thereof.
[1898] Embodiment 30. A compound selected from:
[1899]
[1900] or a pharmaceutically acceptable salt thereof.
[1901]
[1902] 121
[1903] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1904]
[1905] or a pharmaceutically acceptable salt thereof.
[1906] Embodiment 32. A compound selected from:
[1907]
[1908] or a pharmaceutically acceptable salt thereof.
[1909] Embodiment 33. The compound of numbered embodiment 1 , wherein the compound selected from the group consisting of:
[1910]
[1911] 122
[1912] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1913]
[1914] 123
[1915] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1916]
[1917] 124
[1918] 82684654v1Attorney Docket No.: 777812: CAT-036PC
[1919]
[1920] 125
[1921] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1922]
[1923] or a pharmaceutically acceptable salt thereof.
[1924] Embodiment 34. The compound of numbered embodiment 9, wherein the compound selected from the group consisting of:
[1925]
[1926] 126
[1927] 82684654v1Atorney Docket No.: 777812: CAT-036PC
[1928]
[1929] 127 82684654v1
Claims
Atorney Docket No.: 777812: CAT-036PCCLAIMS1. A compound of Formula I*:RPG2N RA'or a pharmaceutically acceptable salt thereof;wherein:RBis H, -C1-3 alkyl-Ce-w aryl, or-Ci-3 alkyl-Ce-w carbocyclyl, wherein -C1-3 alkyl-Ce-w aryl is optionally substituted with one or more of halo, pseudohalo, C1-3 alkyl, C1-3 haloalkyl, -C(O)H, -CC>2-(Ci-6 alkyl), 5- to 7-membered heterocycloalkyl, -CH2NR2, -CH2OR, -C(O)R, -CN, -N2X, or -NR2; wherein -C1-3 alkyl-Ce-w carbocyclyl is optionally substituted with one or more of halo, pseudohalo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;each R is independently H or C1-3 alkyl;X is a counterion;RPG2is a pyrrolidine protecting group; andRAis RCAor RD;wherein:RCAis a chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative; andRDis C1-3 heteroal kyl-Ce-w aryl, optionally substituted with one or more of halo, C1-3 alkyl, or C1-3 alkoxy.
2. The compound of claim 1 , wherein the compound of Formula I* is a compound of Formula I:RpG2NRB(i);or a pharmaceutically acceptable salt thereof;wherein:RBis H, -C1-3 alkyl-Ce-w aryl, or-Ci-3 alkyl-Ce-w carbocyclyl, wherein -C1-3 alkyl-Ce-w aryl is optionally substituted with one or more of halo, pseudohalo, C1-3 alkyl, C1-3 haloalkyl, -C(O)H, -CC>2-(Ci-6 alkyl), 5- to 7-membered heterocycloalkyl, -CH2NR2, -CH2OR, -C(O)R, -CN, -N2X, or -NR2; wherein -C1-3 alkyl-Ce-w carbocyclyl is optionally substituted with one or12882684654v1Atorney Docket No.: 777812: CAT-036PCmore of halo, pseudohalo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;each R is independently H or C1-3 alkyl;RPG2is a pyrrolidine protecting group; andRAis RCAor RD;wherein:RCAis a chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative; andRDis C1-3 heteroal kyl-Ce-w aryl, optionally substituted with one or more of halo, C1-3 alkyl, or C1-3 alkoxy.
3. The compound of claim 2, wherein the compound of Formula I is a compound of Formula II:RPG2RB(II),or a pharmaceutically acceptable salt thereof;wherein:RBis H, -C1-3 alkyl-Ce-w aryl, or-Ci-3 alkyl-Ce-w carbocyclyl, wherein -C1-3 alkyl-Ce-w aryl is optionally substituted with one or more of halo, pseudohalo, C1-3 alkyl, C1-3 haloalkyl, -C(O)H, -CC>2-(Ci-6 alkyl), 5- to 7-membered heterocycloalkyl, -CH2NR2, -CH2OR, -C(O)R, -CN, -N2X, or -NR2; wherein -C1-3 alkyl-Ce-w carbocyclyl is optionally substituted with one or more of halo, pseudohalo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;X is a counterion;each R is independently H or C1-3 alkyl;RPG2is a pyrrolidine protecting group; andRCAis a chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative.
4. The compound of claim 2, wherein the compound of Formula II is a compound of Formula III:RPG2Owherein:12982684654v1Atorney Docket No.: 777812: CAT-036PCRPG2is a pyrrolidine protecting group; andRCAis a chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative.
5. The compound of claim 4, wherein the compound of Formula III is a compound of Formula lll-A:RPG2OH Me (Hl-A),wherein:RPG2is a pyrrolidine protecting group;RA1and RA2are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RA1and RA2are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; andeach R is independently H or C1-3 alkyl.
6. The compound of claim 4, wherein the compound of Formula III is a compound of Formula lll-B:RPG2wherein:RPG2is a pyrrolidine protecting group;RB1, RB2, and RB3are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RB1, RB2, and RB3are each optionally substituted one or more times with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; andeach R is independently H or C1-3 alkyl.13082684654v1Atorney Docket No.: 777812: CAT-036PC7. The compound of claim 4, wherein the compound of Formula III is a compound of Formula lll-C:RPG2pC°r,C3NNR (lll-C),wherein:RPG2is a pyrrolidine protecting group;RC1, RC2, and RC3are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RC1, RC2, and RC3are each optionally substituted one or more times with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; andeach R is independently H or C1-3 alkyl.
8. The compound of claim 4, wherein the compound of Formula III is a compound of Formula lll-D:RPG2n n Nor a pharmaceutically acceptable salt thereof;wherein:RPG2is a pyrrolidine protecting group.
9. The compound of claim 2, wherein the compound of Formula II is a compound of Formula IV:RPG2N12or a pharmaceutically acceptable salt thereof;wherein:13182684654v1Atorney Docket No.: 777812: CAT-036PCR2is halo, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-3 haloalkyl, -CH2NR2, -CH2O-PG, -CH2OR, -C(O)R, -CN, -N2X, or -NR2; -C1-3 alkyl-Ce-w carbocyclyl, optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;X is counterion;each R is independently H or C1-3 alkyl;PG is a protecting group;RPG2is a pyrrolidine protecting group; andRCAis a chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative.
10. The compound of claim 9, wherein the compound of Formula IV is a compound of Formula IV-A:RPG2R2(IV-A),wherein:R2is halo, pseudohalo, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-3 haloalkyl, -CH2NR2, -CH2O-PG, -CH2OR, -C(O)R, -CN, -N2X, or-NR2; -C1-3 alkyl-Ce-w carbocyclyl, optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;X is counterion;PG is a protecting group;RPG2is a pyrrolidine protecting group;RA1and RA2are each independently C1-3 alkyl, C1-3 haloalkyl, Ce-w aryl, Ce-w haloaryl, or 5-10 membered heteroaryl, wherein RA1and RA2are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl Ce-w aryl, -CN, -NR2, -OR; andeach R is independently H or C1-3 alkyl.13282684654v1Atorney Docket No.: 777812: CAT-036PC11. The compound of claim 9, wherein the compound of Formula IV is a compound of Formula IV-B:RPG2R2(IV-B),wherein:R2is halo, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-3 haloalkyl, -CH2NR2, -CH2O-PG, -CH2OR, -C(O)R, -CN, -N2X, or -NR2; -C1-3 alkyl-Ce-w carbocyclyl, optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;X is counterion;PG is a protecting group;RPG2is a pyrrolidine protecting group;RB1, RB2, and RB3are each independently C1-3 alkyl, C1-3 haloalkyl, Ce-w aryl, Ce-w haloaryl, or 5-10 membered heteroaryl, wherein RB1, RB2, and RB3are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl Ce-w aryl, -CN, -NR2, -OR; andeach R is independently H or C1-3 alkyl.
12. The compound of claim 9, wherein the compound of Formula IV is a compound of Formula IV-C:RpG2 / RC2 RC3On.O^N,RC,"QR2(IV-C),wherein:R2is halo, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-3 haloalkyl, -CH2NR2, -CH2O-PG, - CH2OR, -C(O)R, -CN, -N2X, -NR2, or-Ci-3 alkyl-Ce-w carbocyclyl, wherein -C1-3 alkyl-Ce-w carbocyclyl is optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, - CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;X is counterion;PG is a protecting group;RPG2is a pyrrolidine protecting group;13382684654v1Atorney Docket No.: 777812: CAT-036PCRC1, R , and RC3are each independently C1-3 alkyl, C1-3 haloalkyl, Ce-w aryl, Ce-w haloaryl, or 5-10 membered heteroaryl, wherein RC1, RC2, and RC3are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl Ce-w aryl, -CN, -NR2, -OR; andeach R is independently H or C1-3 alkyl.
13. The compound of claim 9, wherein the compound of Formula IV is a compound of Formula IV-D:RPG2NPhi N>2or a pharmaceutically acceptable salt thereof;wherein:R2is halo, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-3 haloalkyl, -CH2NR2, -CH2O-PG, -CH2OR, -C(O)R, -CN, -N2X, -NR2, or-Ci-3 alkyl-Ce-w carbocyclyl, wherein -C1-3 alkyl-Ce-w carbocyclyl is optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;X is counterion;PG is a protecting group;each R is independently H or C1-3 alkyl; andRPG2is a pyrrolidine protecting group.
14. A compound of Formula lll-E:RPG2N7— RE2E1or a pharmaceutically acceptable salt thereof;wherein:RPG2is a pyrrolidine protecting group;13482684654v1Atorney Docket No.: 777812: CAT-036PCRE1and RE2are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RE1and RE2are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR;RE3and RE4are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RE1and RE2are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; andeach R is independently H or C1-3 alkyl.
15. A compound of Formula (IV-E):or a pharmaceutically acceptable salt thereof;wherein:R2is halo, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-3 haloalkyl, -CH2NR2, -CH2O-PG, -CH2OR, -C(O)R, -CN, -N2X, or -NR2; -C1-3 alkyl-Ce- carbocyclyl, optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;X is counterion;PG is a protecting group;each R is independently H or C1-3 alkyl;RPG2is a pyrrolidine protecting group;RE1and RE2are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RE1and RE2are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR;RE3and RE4are each independently C1-3 alkyl, C1-3 haloalkyl, C6-12 aryl, C6-12 haloaryl, or 5-10 membered heteroaryl, wherein RE1and RE2are each optionally further substituted with halo, C1-3 alkyl, C1-3 haloalkyl C6-12 aryl, -CN, -NR2, -OR; andeach R is independently H or C1-3 alkyl.13582684654v1Atorney Docket No.: 777812: CAT-036PC16. A compound of Formula V or Formula VI:RPG2or a pharmaceutically acceptable salt thereof,wherein:R5is halo or pseudohalo;each RPG1is a carboxylic acid protecting group;each RPG2is a pyrrolidine protecting group; andeach RPG3is an amine protecting group; andRCAis a chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative.
17. The compound of any one of the previous claims, or a pharmaceutically acceptable salt thereof; wherein RPG2is a pyrrolidine protecting group selected from the group consisting of: Boc (tert-Butyloxycarbonyl), Fmoc (9-Fluorenylmethoxycarbonyl), Cbz (Benzyloxycarbonyl), Acetyl (Ac), Trityl (Triphenylmethyl), Benzyl (Bn), Allyl (All), p-Toluenesulfonamide (Ts), allyloxycarbonyl (Alloc), propargyloxycarbonyl (Proc), pivaloyl (Piv), trimethylsilyl (TMS), tert-butyldimethylsilyl (TBDMS), triisopropylsilyl (TIPS), 4-methylbenzenesulfonyl (Ms), 4-bromobenzenesulfonyl (BrMs), Phthalimide, and Trifluoroacetamide, Teoc (2-(Trimethylsilyl)ethoxycarbonyl), Troc (2,2,2-Trichloroethoxycarbonyl), Azoc (Azidomethoxycarbonyl), p-Nitrobenzyloxycarbonyl (pNZ), 2-Chloro-benzyloxycarbonyl (2-CI-Z), Nosyl (Ns, Nitrobenzenesulfonyl), o-Nitrobenzenesulfonyl (oNBS), 2,4-Dinitrobenzenesulfonyl (dNBS), Benzothiazole-2-sulfonyl (Bts), 2-(4-Nitrophenylsulfonyl)ethoxycarbonyl (Nsc), Dde (1-(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl), ivDde (1-(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)isovaleryl), Mtt (4-Methyltrityl), Mmt (4-Methoxytrityl), Pbf (2, 2, 4,6,7- Pentamethyldihydrobenzofuran-5-sulfonyl), Pmc (2,2,5,7,8-Pentamethylchroman-6-sulfonyl),13682684654v1Atorney Docket No.: 777812: CAT-036PCMtr (4-Methoxy-2,3,6-trimethylbenzenesulfonyl), o-Nitrobenzyl (oNZ), NVOC (6-N itroveratryloxycarbonyl) , N PPOC (2-(2-N itrophenyl)propoxycarbonyl) .
18. The compound of claim 1, wherein the compound selected from the group consisting of:13782684654v1Atorney Docket No.: 777812: CAT-036PC13882684654v1Atorney Docket No.: 777812: CAT-036PC13982684654v1Attorney Docket No.: 777812: CAT-036PCor a pharmaceutically acceptable salt thereof.14082684654v1Atorney Docket No.: 777812: CAT-036PC19. The compound of claim 18, wherein the compound selected from the group consisting of:Bocor a pharmaceutically acceptable salt thereof.
20. A process for preparing a compound of Formula (IV), Formula (Xlll-A), or Formula (I*), wherein:(a) the compound prepared is a compound of Formula (I*):RpG2RB(i*);or a pharmaceutically acceptable salt thereof;wherein:RPG2is a pyrrolidine protecting group;RBis -C1-3 alkyl-Ce- aryl substituted with -C(O)H;each R is independently H or C1-3 alkyl;RAis RD, wherein:14182684654v1Atorney Docket No.: 777812: CAT-036PCRDis C1-5 heteroalkyl or C1-3 heteroalkyl-Ce- aryl; wherein each is optionally substituted with one or more of halo, C1-3 alkyl, or C1-3 alkoxy; and the process comprises palladium-catalyzed carbonylation of a compound of Formula (Xlll-A):(Xlll-A),or a pharmaceutically acceptable salt thereof,wherein:R2is halo or pseudohalo;each R is independently H or C1-3 alkyl;RPG2is a pyrrolidine protecting group; andR4is C1-5 alkyl or -C1-3 alkyl-Ce-i2aryl, wherein each is optionally further substituted by halo, C1-3 alkyl, or C1-3 alkoxy;to form the compound of Formula (I*);(b) the compound prepared is a compound of Formula (Xlll-A):RPG2(Xlll-A),and the process comprises thioesterification of a compound of Formula (IV):RPG2OX)R2(IV),or a pharmaceutically acceptable salt thereof;wherein:RCAis a chiral auxiliary, provided that the chiral auxiliary is not an oxazolidinone derivative;14282684654v1Atorney Docket No.: 777812: CAT-036PCto form the compound of Formula (Xlll-A); and(c) the compound prepared is a compound of Formula (IV):RPG2>2or a pharmaceutically acceptable salt thereof;and the process comprises asymmetric alkylation of a compound of Formula (III):RPG2NRwith a compound of Formula (XVI):wherein:R5is halo or pseudohalo;to form the compound of Formula (IV).
21. A process for preparing a compound of Formula (IV), Formula (Xlll-A), or Formula (I*), wherein:(a) the compound prepared is a compound of Formula (I*):RPG2Nor a pharmaceutically acceptable salt thereof;wherein:RPG2is a pyrrolidine protecting group;RBis -C1-3 alkyl-Ce- aryl substituted with-C(O)H;each R is independently H or C1-3 alkyl;RAis RD, wherein:RDis C1-5 heteroalkyl or C1-3 heteroalkyl-Ce- aryl; wherein each is optionally substituted with one or more of halo, C1-3 alkyl, or C1-3 alkoxy; and14382684654v1Atorney Docket No.: 777812: CAT-036PCthe process comprises palladium-catalyzed carbonylation of a compound of Formula (Xlll-A):(Xlll-A),or a pharmaceutically acceptable salt thereof,wherein:R2is halo or pseudohalo;RPG2is a pyrrolidine protecting group; andR4is C1-5 alkyl, Ce-i2aryl, or -C1-3 alkyl-Ce-i2aryl , wherein each is optionally further substituted by halo, C1-3 alkyl, or C1-3 alkoxy;to form the compound of Formula (I*);(b) the compound prepared is a compound of Formula (Xlll-A):RPG2(Xlll-A),and the process comprises thioesterification of a compound of Formula (IV):RPG2OX)R2(IV),or a pharmaceutically acceptable salt thereof;wherein:RCAis a chiral auxiliary;to form the compound of Formula (Xlll-A); and(c) the compound prepared is a compound of Formula (IV):14482684654v1Atorney Docket No.: 777812: CAT-036PCRPG2o NRCA'R2(IV),or a pharmaceutically acceptable salt thereof;and the process comprises asymmetric alkylation of a compound of Formula (III):RPG2o NRGA'with a compound of Formula (XVI):R2R5(XVI),wherein:R5is halo or pseudohalo;to form the compound of Formula (IV).
22. A process for preparing Compound 1, Compound 2, Compound 3, or Compound 4, wherein:(a) the compound prepared is Compound 1:(1),or a salt thereof;comprising reacting Compound 2:14582684654v1Atorney Docket No.: 777812: CAT-036PCor a salt thereof;with a palladium catalyst and a carbon monoxide source to produce Compound 1 ; (b) the compound prepared is Compound 2:Boc23. A process for preparing Compound 1 :or a salt thereof,the process comprising:(a) reacting Compound 4:of a salt thereof, with Compound 5:Br(5),and at least one base to produce Compound 3:82684654v1Atorney Docket No.: 777812: CAT-036PCor a salt thereof;(b) reacting Compound 3, or a salt thereof, with Compound 6:SH(6),or a salt thereof, to produce Compound 2:or a salt thereof;(c) reacting Compound 2 with a palladium catalyst and a carbon monoxide source to produce Compound 1.
24. A compound of Formula XII l-A:RpG2or a pharmaceutically acceptable salt thereof,wherein:R2is halo, pseudohalo, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-3 haloalkyl, -CH2NR2, -CH2O-PG, -CH2OR, -C(O)R, -CN, -N2X, -NR2, or-Ci-3 alkyl-Ce-w carbocyclyl; wherein -C1-3 alkyl-Ce-w carbocyclyl optionally substituted with one or more of halo, C1-3 alkyl, C1-3 haloalkyl, -CH2NH2, -C(O)R, -CO2R, -CN, -N2X, or-NR2;X is counterion;each R is independently H or C1-3 alkyl;PG is a protecting group;RPG2is a pyrrolidine protecting group; andR4is Ci-6 alkyl, C6-i2aryl, or -C1.3 alkyl-C6-i2aryl.
25. The process of claim 20 or 21 , wherein:RPG2is a pyrrolidine protecting group;14782684654v1Atorney Docket No.: 777812: CAT-036PCRBis -Ci alkyl-Ce aryl substituted with -C(O)H; andRAis RD, wherein RDis C2 heteroalkyl-Cearyl optionally substituted with one or more of halo, or C1-3 alkoxy; and the hetero group is sulfur.14882684654v1
